Published in final edited form as:

Eur J Med Chem. 2009 June ; 44(6): 2434–2446. doi:10.1016/j.ejmech.2009.01.011.

Highly Twisted Adamantyl Arotinoids: Synthesis, Antiproliferative Effects and RXR Transactivation Profiles

Santiago Pérez-Rodríguez^a, Maria A. Ortiz^b, Raquel Pereira^a, Fátima Rodríguez-Barrios^a, Ángel R. de Lera^{a,*}, and F. Javier Piedrafita^{b,*}

^a Departamento de Química Orgánica, Universidade de Vigo, Lagoas-Marcosende, 36310 Vigo, Spain

^b Sidney Kimmel Cancer Center, 10905 Road to the Cure, San Diego, CA 92121

Abstract

Retinoid-related molecules with an adamantyl group (adamantyl arotinoids) have been described with selective activities towards the retinoid receptors as agonists for NR1B2 and NR1B3 (RAR β , γ) (CD437, MX3350-1) or RAR antagonists (MX781) that induce growth arrest and apoptosis in cancer cells. Since these molecules induce apoptosis independently of RAR transactivation, we set up to synthesize novel analogs with impaired RAR binding. Here we describe adamantyl arotinoids with 2,2'-disubstituted biaryl rings prepared using the Suzuki coupling of the corresponding fragments. Those with cinnamic and naphthoic acid end groups showed significant antiproliferative activity in several cancer cell lines, and this effect correlated with the induction of apoptosis as measured by caspase activity. Strikingly, some of these compounds, whereas devoid of RAR binding capacity, were able to activate RXR.

Keywords

Adamantyl arotinoids; retinoid-related molecules (RRMs); RXR; apoptosis; synthesis

1. INTRODUCTION

Vitamin A (retinol) and its derivatives, the retinoids, are essential regulators of many biological events including cell growth and differentiation, development, homeostasis and carcinogenesis. Because of their antiproliferative activity, retinoids have been proposed as cancer preventive and chemotherapeutic agents [1]. Retinoid signals are mediated by the retinoid receptors RAR α , β , γ (NR1B1, 2, 3) and RXR α , β , γ (NR2B1, 2, 3) [2,3], which belong to the superfamily of nuclear hormone receptors [4]. These are ligand-activated transcription factors that bind to specific DNA sequences in the regulatory regions of target genes. In the absence of ligand, RAR/RXR heterodimers interact with co-repressors and bind DNA to inhibit transcription. Ligand binding induces a profound conformational change in the ligand binding domain of the receptors causing the dissociation of the co-repressor complex and the re-positioning of the activation function-2 located in helix H12. This exposes a LXXLL motif

*Corresponding authors: Angel R. de Lera, Tel: +34-986-812316 Fax +34-986-811940 E-mail: qolera@uvigo.es (AdL); F. Javier Piedrafita, Tel: +01-858-410-4188. Fax: +01-858-450-3251. E-mail: jpiedrafita@skcc.org (FJP).

Publisher's Disclaimer: This is a PDF file of an unedited manuscript that has been accepted for publication. As a service to our customers we are providing this early version of the manuscript. The manuscript will undergo copyediting, typesetting, and review of the resulting proof before it is published in its final citable form. Please note that during the production process errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.

necessary for the recruitment of chromatin-modifying co-activators and the RNA polymerase II transcriptional machinery to initiate transcription (see [5,6] and references therein).

Despite their promising activity *in vitro*, most natural and synthetic retinoid analogs exhibit significant toxicity that has limited their oncological therapeutic use [7]. All-*trans*-retinoic acid (atRA) is used as a differentiation agent against acute promyelocytic leukaemia [8], whereas the synthetic RXR agonist LGD1069 (Targretin®) has been approved for the treatment of cutaneous T cell lymphoma [9] and is being clinically evaluated against lung and breast cancers [10]. Other retinoid analogs are currently under clinical evaluation with mixed results [1]. The development of novel retinoids with selectivity towards RXRs or the different RAR subtypes and isoforms has led to the intriguing discovery of a novel class of derivatives with strong pro-apoptotic activity [11]. Because they often exert their anticancer activity independently of the retinoid receptors, they are also known as atypical retinoids or retinoid-related molecules (RRMs). In particular CD437 **1**, a RAR β / γ -selective agonist and several analogs that contain an adamantyl group are classified as adamantyl arotinoids (AdArs). A small number of RRM are known to induce apoptosis in cancer cells. These include anhydroretinol [12,13], 4-hydroxyphenylretinamide (4-HPR) [14], some heteroarotinoids [15], and a few AdArs (MX781 **9**, CD2325 **2** and their analogs, Figure 1) [16].

CD437 **1** is the prototype of the RRM subfamily of RAR β / γ -selective AdAr agonists [11] that includes CD2325 **2**, MX2870-1 **3**, and MX3350-1 **4** (Figure 1). CD437 **1** was first shown to induce growth arrest and apoptosis in breast cancer cells [17] and several AdArs were later found to inhibit growth of numerous cancer cell lines *in vitro* and in animal models (see [16] and references therein). Given that AdArs inhibit cell growth independently of RAR transactivation [18–20], great efforts have aimed at characterizing the mechanism of AdAr-induced apoptosis and, ultimately, at identifying AdAr targets that mediate their anticancer activity. Thus, CD437 **1**-induced apoptosis requires transcription/translation in a cell-type dependent manner [21–24] (reviewed in [16]), and caspases are activated via the mitochondrial pathway [22,25–27], although a role for death-receptor signalling has also been suggested with some compounds [28–30]. CD437 **1** and AdArs alike cause a strong and sustained activation of JNK and p38 stress kinases that precedes the release of cytochrome c and subsequent induction of apoptosis [31]; however, contrasting results have been reported by different laboratories using a variety of kinase inhibitors and cell lines [32–36]. In contrast to the activation of JNK/p38 MAPKs, certain apoptotic AdArs target the IKK/NF κ B signalling pathway [20], which evokes survival signals [37]. MX781 **9** and CD2325 **2** significantly inhibited kinase activity of immunopurified IKK complex *in vitro* [20]; furthermore, using purified recombinant kinases we have recently proved that MX781 **9** is a selective inhibitor of IKK β and several analogs have been prepared with enhanced anti-IKK β and growth inhibitory activities [38]. Our findings disagree with recent reports indicating that CD437 **1** and its analog 3-Cl-AHPC **7** induced apoptosis via activation of NF κ B [39,40].

Second generation AdArs have been described with improved anticancer activity [36,41–43]. Cinnamic acid derivative ST1926 (AHPC) **6** activates RAR γ and induces apoptosis in various cancer cell lines with stronger potency as compared to CD437 **1** [44,45]. Derivatives of CD437 **1** lacking RAR transactivation activity, most notably 3-Cl-AHPN (MM11453) [41], 3-Cl-AHPC **7** [43,46], and 5-Cl-AHPN **5** [47], also elicit anticancer activity comparable to the parent compound, whereas derivative 3-A-AHPC **8** prevented the induction of apoptosis by CD437 **1** analogs but did not inhibit their effect on cell cycle [47]. 3-Cl-AHPC **7** is an AdAr with cinnamic acid substructure (Figure 1) that induces cell-cycle arrest and apoptosis in several cancer cell lines. Induction of apoptosis by 3-Cl-AHPC **7** and some of its analogs was later shown to occur through binding to the nuclear receptor SHP (small heterodimer partner, NR0B2) [48].

With the exception of IKK β [20,38] and SHP [48], the cellular targets that mediate the anticancer activity of these AdArs are largely unknown, which represents a significant drawback for the drug development efforts. Existing SAR studies of the RRM family of compounds have shown the important synergistic role of the adamantyl and phenol groups on RAR binding selectivity [49]. Moreover, the bulky adamantyl group appears to be necessary for anticancer activity but not sufficient, since several other AdArs exhibit low or moderate activity. The carboxylic acid might play a role in apoptosis because its replacement by other bioisosters and related groups led to reduction or loss of activity [50].

Previous docking studies in the RAR γ LBD of 5-Cl-AHPN **5**, 3-Cl-AHPC **7** and analogs have revealed that the steric clash of the substituents located ortho to the biaryl bond (chloro, 3-acetamidopropoxy of **8**) induce a twist of that bond that displaces the adamantyl fragment from the coplanarity with the aromatic rings of their polar termini (naphthoic acid of CD437 or cinnamic acid of AHPC) [47]. As a consequence, the position of helix H12 is not appropriate for the interaction with the co-activator [51,52], and the transactivation activities are considerably reduced [47]. Nevertheless, competition experiments with [^3H]-9cRA revealed that 3-Cl-AHPC **7** efficiently and selectively competed with the native ligand for binding to RAR γ (83% displacement; cf. 31% RAR α , 17% RAR β , 16% RXR α). Further analysis led to the suggestion that the conformational effect induced by 3-Cl-AHPC **7** was not sufficient to induce dissociation of co-repressors and association of co-activators, and therefore the ligand apparently behaved as a transactivational antagonist for RAR γ [47].

Based on this model, we considered to further increase the steric interactions on that region by incorporation of two substituents (Cl and Me) at the vicinal positions of the biaryl connection, which would further impair binding of the ligand to the RAR receptor subtypes. Moreover, to additionally increase the bulk of the analogs, we considered the incorporation of a MEM substituent on the phenol after recognizing that the combined effect of the acetal and the adamantyl group of MX781 **9** is likely associated to its RAR antagonistic properties. In addition to the naphthoic acid derivatives of CD437 **1**, other conformationally more flexible polar chains of arylacetic and cinnamic acids were also considered (Scheme 1). These AdArs were evaluated with regard to their ability to inhibit cancer cell proliferation and induce apoptosis. Interestingly, we found that while the anticancer effects are independent of RAR transactivation, some of these highly twisted analogs bind and transactivate through RXR.

2. CHEMISTRY

The Suzuki coupling between an arylboronic acid and an aryl triflate, a strategy also utilized by Dawson *et al.* [47], was chosen as a key step of the synthetic sequence to generate the highly congested 2,2'-disubstituted biaryl bond (Scheme 1). The greater tolerance to steric hindrance of the Suzuki reaction relative to other palladium-catalyzed cross-coupling variants is well established [53,54].

Incorporation of the adamantyl group using a Friedel-Crafts alkylation of 4-bromo-3-methylphenol **10** with adamant-1-ol proceeded uneventfully and in excellent yield (98%). Protection of the phenol as silyl ether **12**, followed by bromine-lithium exchange (*n*-BuLi, THF, -78°C) and trapping the aryllithium with tri-isopropylborate produced the corresponding di-isopropylboronate, which was hydrolyzed with HCl to afford **13**. This unstable boronic acid was used in the next step without further purification. The synthesis of triflate **14** from commercially available 6-hydroxynaphthoic acid has been described previously [47]. Aryl triflate **17** [55] was in turn prepared in two steps from commercial 3-chloro-4-hydroxyphenylacetic acid **15**, via ester **16** (obtained from **15** by treatment with TMSCHN $_2$ at ambient temperature), which was then treated with TFAC in pyridine to afford the desired sulphonate (82%). In anticipation of the application of the Horner-Wadsworth-Emmons

reaction to afford the cinnamic ester, commercially available 3-chloro-4-hydroxybenzaldehyde **18** was treated with trifluoromethanesulphonic anhydride in pyridine to furnish triflate **19**. The condensation of the latter under the conditions described by Bates *et al.* [56] provided cinnamate *E*-**20** in 55% yield as the only geometric isomer (Scheme 1).

After exploring different conditions for the Suzuki coupling of **13** and triflate **17** as a model system, we obtained higher yields using those of Cockerill *et al* [57], which involve heating to 90 °C [Et₃N, Pd(PPh₃)₄, DMF, 27.5 h] thoroughly degassed reaction mixtures of **13** and **17**. Worthy of note, all attempts to scale-up the reaction led to erosion in the yield of **21**. The same protocol served well for the coupling of the naphthyl triflate **14** to the same boronic acid, which delivered **26** in 85% yield (Scheme 1). Exploiting the acceleration effect of microwave irradiation [58] the reaction reached completion after 15 min at 70 °C, but the yield decreased (63%). The optimized reaction conditions did not serve well for triflate **20**, since it afforded **31** in disappointing yields (34%). Turning to the precedent approach to 3-Cl-AHPC **7** by Zhang *et al.* [43,47], which used Pd(PPh₃)₄ as pre-catalyst, Na₂CO₃ as base and LiCl as additive in DME, the coupled product **31** (67%) was instead obtained after 22 h heating at 80 °C. No improvement of the yield for this coupling was observed using microwave irradiation. Deprotection of the silyl ether of all analogs with TBAF in THF at 0 °C was followed by treatment of the phenols with MEMCl using NaH in DMF at 0 °C to furnish in moderate yields derivatives **23**, **28** and **33**. Finally, saponification (aq. K₂CO₃, MeOH, 70 °C) produced the desired carboxylic acids **24**, **29** and **34**, respectively. The same conditions were used for the synthesis of the adamantyl arotinoids **25**, **30** and **35**.

3. RESULTS

3.1 Inhibition of cancer cell proliferation by novel AdArs

We first evaluated the effect of the new AdAr analogs on Jurkat T leukaemia cells, which are very sensitive to the antiproliferative activity of RRM. Figure 2 shows that the parent compounds CD2325 **2** and MX781 **9** strongly inhibited Jurkat cell proliferation in a dose-dependent manner, with estimated IC₅₀ values of 0.082 and 0.287 µM, respectively, after 48 h of treatment. Among the synthesized compounds, the naphthoic acid derivatives **30** (IC₅₀ 0.435 µM) and **29** (IC₅₀ 0.707 µM) were the most active against Jurkat cells, followed by the cinnamic analogs **35** (IC₅₀ 1.414 µM) and **34** (IC₅₀ 1.866 µM). Compounds **24** and **25** were noticeably less effective and only partial inhibition was seen at higher concentrations. As expected, the antiproliferative activity of the AdArs was dependent on the time of incubation (data not shown).

We next examined the antiproliferative activity of the analogs against a panel of cancer cell lines of diverse epithelial origin. Higher concentrations of AdArs are usually required to inhibit growth of those cells as compared to Jurkat cells and table 1 summarizes the percentage of growth inhibition observed in the presence of 4 µM of the different AdArs. As observed with the most sensitive Jurkat T cell line, **29** and **30** were the most active of the new derivatives, with similar or even increased activity as compared to parent AdArs CD2325 **2** and MX781 **9**. It is evident that **34** exhibited strong antiproliferative activity with comparable or enhanced activity than MX781 **9** against ovarian (SkOV3), lung (A549), and pancreatic (MiaPaCa-2) cancer cells (Table 1), despite limited activity in Jurkat cells (see fig. 2). We included 3-Cl-AHPC **7** in our cell proliferation studies for comparison and found strong antiproliferative activity against all cell lines evaluated, which was identical to that elicited by CD2325 **2** (data not shown).

3.2. AdArs induce apoptosis in cancer cells

The activation of caspases is an early event in apoptosis [59]. To evaluate the pro-apoptotic activity of the novel AdArs we examined the induction of DEVDase activity as a measure of caspases 3/7 activity in Jurkat T cells after short periods of treatment. Figure 3 illustrates that AdArs CD2325 **2** and MX781 **9** provoked a robust induction of DEVDase activity when tested at 1 and 4 μM . Similar activation was observed in the presence of **30** as well as 1 μM 3-Cl-AHPC **7**. The MEM derivative **29** also induced substantial DEVDase activity but only when tested at 4 μM (Figure 3). Likewise, the phenols **25** and **35** activated caspases 3 and 7 only at the highest concentration. This parallel with diminished antiproliferative activity observed at low concentrations of **25**, **29**, and **35** (see Fig. 2). In contrast to the pro-apoptotic activity of **29**, other MEM-functionalized compounds showed limited (**24**) or no activity (**34**). In general, the induction of DEVDase activity correlated well with the antiproliferative activity measured by MTT assay described in Figure 2. The small differences observed between those two activities are possibly due to delays in the activation of caspases.

3.3. RAR/RXR transactivation activity

We used transient transfections in CV-1 cells with expression vectors containing the Gal4 DNA binding domain fused to the C-terminus ligand binding domain (LBD) of RAR α , β , γ or RXR α to evaluate the transactivation potential of the novel AdArs. As shown in Figure 4A, none of the compounds was able to induce luciferase activity in the presence of RAR α . Likewise, all the analogs were inactive on Gal4-RAR β and Gal4-RAR γ proteins (data not shown). The ability to function as RAR antagonists was next evaluated in CV-1 cells stimulated with 20 nM atRA. Testing compounds were added in excess of 10 (0.2 μM), 40 (0.8 μM), or 200 fold (4 μM) with respect to the natural ligand. Only the MEM derivative **24** had a significant effect on RAR α activity (43.7% inhibition) when tested at the highest concentration of 4 μM , whereas the other MEM analogs **29** and **34** and the phenol **30** inhibited RAR α activity by 27–32% (Fig. 4B). Lower concentrations of those derivatives had no significant effect on atRA-mediated RAR α activity. This contrasts with the 90% inhibition elicited by the parental compound MX781 **9** at the same concentration and the total inhibition of RAR activity observed even with lower concentrations of the inverse agonist **UVI2024** (BMS204493, see structure in Figure 6) [60]. When the same experiment was performed with Gal4-RAR β and Gal4-RAR γ , the new AdArs failed to inhibit atRA-mediated RAR β and RAR γ transactivation even at the 200 fold molar excess concentration, which contrasts with the almost complete inhibition of both RAR β and RAR γ seen with **UVI2024** at any given concentration or with MX781 **9** at 4 μM (data not shown).

The effect of the AdArs RXR α transactivation is illustrated in Figure 5. To our surprise, phenol **35** and all new MEM-containing AdArs (**24**, **29**, and **34**) were capable of inducing RXR α -dependent luciferase activity almost as efficiently as the natural ligand 9cRA **36** (Figure 5A), and this transactivation was inhibited by the RXR antagonist UVI3003 **38** (Figure 5B) [61]. Whereas **29** behaved as a partial agonist and reached a maximum activity of ~45% of that seen in the presence of saturating concentrations of 9cRA **36** or the RXR agonist LGD1069 **37** (Figure 6), the other analogs activated RXR α with similar or even enhanced potency as compared to the natural ligand (Figure 5C). The EC₅₀ values estimated for **29**, **34**, and **35** were 0.667 μM , 0.60 μM , and 0.576 μM , respectively. Compound **24** activated RXR α with an EC₅₀ of 1.137 μM . These values were higher than those observed with 9cRA **36** (0.2 μM) or LGD1069 **37** (0.04 μM) (not shown).

This unexpected result prompted us to use Molecular Docking studies in order to justify the rexinoid profile of the AdArs. The complexes obtained upon replacement of 9cRA by the synthesized AdAr into the crystal structure of human holo-RXR α (PDB code 1k74) [62] were analyzed. Analysis of the most populated clusters found by AutoDock for **35** [root-mean-square

deviation (rmsd) < 1.0 Å] indicate that it binds RXR α similarly to 9cRA **36** (Figure 7). The ligand **35** is buried in an essentially hydrophobic pocket formed by residues located on helices, H3, H5, H7 and H11, and the β -turn. The elongated pocket is sealed by Arg 316 of helix H5 on one side and by the transactivation helix H12 on the other side. The carboxylate group of **35** like that of 9cRA is sandwiched between the side chains of residues Phe313, Ala271 and Ala272, which form a hydrophobic tunnel. The ionic interaction between the carboxylate group and Arg316 is similar to that seen in atRA and 9cRA RAR γ *holo*-LBD structures. At the other side of the pocket, residues Leu433, His435, Val 342, Gly343 and Ile345 make contacts with the adamantyl residue.

Whereas the docking protocol provided good fits for the free phenol (**35**), however, no stabilizing solutions were found for the MEM derivatives (**24**, **29**, **34**) using AutoDock.

4. DISCUSSION

The so called “adamantyl retinoids” [63,64] can structurally be considered as arotenoids [65] (or arene-based retinoids having some of the double bonds included in arenes) with an adamantyl ring in the hydrophobic part of the retinoid structure. Although some bind to and activate the nuclear receptors, the RARs seem dispensable for their anticancer activity [1]. Some analogs show selectivity for certain subtypes of the retinoid receptor and can bind other non-retinoid receptors simultaneously [66,67].

Comprehensive SAR studies on AdArs other than the RAR binding/transactivation are not available and knowledge on the structural requirements that mediate their anticancer activity is insufficient. Provided that AdArs and other atypical retinoids induce apoptosis independently of RARs and RXRs, the identification of the AdAr targets responsible for their anticancer activity will be critical to further optimize the available scaffolds using a structure-based approach and especially focused SAR studies. One such cellular target is IKK β , which is inhibited by MX781 **9** and several analogs *in vitro* and in cell based assays [20,38]. Compound **30** is also a strong inhibitor of recombinant IKK β (our unpublished observations), and this might be partly responsible for the significant antiproliferative activity found against most cancer cell lines (Table 1), although IKK inhibition needs to be confirmed in cellular assays. Another AdAr target is SHP, though 3-Cl-AHPC **7** can induce significant apoptosis in cells lacking SHP [48], and the signalling linking to apoptosis remains to be elucidated. In addition to SHP binding, two analogs of 3-Cl-AHPC **7** were found to inhibit CD45 and SHP-2 protein tyrosine phosphatases *in vitro* at micromolar concentrations [50]. Similarly, CD437 **1** was shown to inhibit recombinant MKP-1 [67]. The effect of RRM on protein phosphatases in cells has yet to be demonstrated, but it is worthy to point out that those 3-Cl-AHPC **7** analogs shown to inhibit CD45 and SHP-2 exhibit very little pro-apoptotic and growth inhibitory activities [50], suggesting that this effect on protein tyrosine phosphatases might not be directly involved in the anticancer power of active AdArs. AdAr-mediated inhibition of MKP-1 on the other hand might be responsible for the sustained activation of JNK and p38 observed by CD437 **1** and other analogs [31], which is likely to play a causal role in the induction of apoptosis by JNK activating stimuli, as demonstrated by others [68–71].

It has been pointed out that the role of the chlorine substituent on the structure and activity of 5-Cl-AHPN **5** appears to go beyond the classical steric effect, since the methyl analog at the same position is considerably less active [47]. We therefore decided to preserve the halogen at that position of the naphthoic acid (or that of the cinnamic acid analogs) and designed a series of analogs with an even greater steric congestion at the biaryl ring bond. The synthesis follows principles already described for the parent analogs and improvements in yields and reaction times have been developed using microwave irradiation for the Suzuki coupling reaction. Of the novel AdArs reported here, the naphthoic derivatives **29** and **30** elicited the

strongest growth inhibition and apoptotic (DEVDase) activities. Similar to 5-Cl-AHPN **5** and 3-Cl-AHPC **7**, the compounds characterized here have no RAR transactivation activity. Contrary to 5-Cl-AHPN **5** and 3-Cl-AHPC **7**, which allegedly function as RAR γ antagonists because of their ability to bind RAR γ but failure to induce release of co-repressors and association of co-activators [47], the synthesized analogs also lack of significant RAR antagonistic activity, with only partial inhibition of RAR α activity observed in the presence of elevated concentrations (200 fold excess) of the MEM analogs **24**, **29**, and **34** or the phenol **30**. To our surprise, the MEM-containing derivatives **24**, **29**, and **34**, activated RXR α . Likewise, the *o*-methyl analog of 3-Cl-AHPC **7**, **35** was also a strong activator of RXR α -driven luciferase activity in our transient transfection assays. Our docking studies could not find good fits of the MEM containing rexinoids **24**, **29**, and **34** within the structure of holo-RXR α . Given the substantial transactivation of RXR α , which was comparable to that of 9cRA **36** with **24** and superior in the presence of **34**, it is possible that an active **24/34**-RXR α conformation might be stabilized by the presence of a particular co-activator or heterodimer partner. In this regard, the crystal structure of the constitutively active RXR α -F318A mutant, which crystallized in the presence of oleic acid, showed an alternate position of helix H12 with the co-activator LXXLL motif not exposed [72]; however, contrary to a pure antagonist, helix H12 was not precluded from adopting an agonist position, which could be stabilized in the presence of co-activators. Future studies will need to evaluate the activity of these rexinoid AdArs on full length RXRs, the activation of different heterodimer partners, and their effects on RXR-co-repressor/co-activator interactions. Furthermore, in base of the recent discovery of RXR subtype preference by certain synthetic rexinoids [73,74], it will be interesting to explore the activation of RXR β and γ by these rexinoid AdArs. Together, all these studies will certainly shed light onto the structural basis of their rexinoid activity.

One important feature of the rexinoid AdArs characterized here is their ability to inhibit cancer cell growth via apoptosis induction, in particular compounds **29** and **35**, although there is no clear correlation between RXR transactivation and induction of caspase activity. For example, **29** is a partial agonist of RXR α and the most effective growth inhibitor of all rexinoid AdArs reported here, whereas **35** has reduced growth inhibitory and apoptosis inducing activities but activates RXR α almost as efficiently as 9cRA **36**. Moreover, **24** and **34** are also effective RXR transactivators but show limited anticancer activity, as does the natural ligand 9cRA **36**, in comparison to other synthetic AdArs. Rexinoids, as well as retinoids, are well known for their significant chemopreventive and therapeutic activity in cancer and rexinoids have the additional advantage of being less toxic [1,75]. In addition to FDA approved Bexarotene (Targretin®, LGD1069), which has residual RAR activity [76], two synthetic rexinoids with no RAR activity, LGD100268 and AGN194204 [76,77], offer improved anticancer activity in preclinical models of breast, lung, and prostate cancer prevention and this anticancer activity is significantly higher in combination with other agents (see [75] for review and references therein). As opposed to rexinoid AdArs **29** and **35**, which produce substantial DEVDase activity in Jurkat T cells (Figure 3), other known rexinoids are poor inducers of apoptosis by themselves [78–81], unless cells are deprived of growth factors [82] or treatment is performed in combination with the estrogen antagonist arzoxifene [80]. Interestingly, LGD100268 seems to inhibit NF κ B activity [80], although a direct effect of the rexinoids on IKK activity has not been yet reported. Contrary to RRM in general, and particularly AdArs, RXRs seem to mediate the growth inhibitory effects of synthetic rexinoids, as the sensitivity of breast cancer cells to AGN194204 correlates with RXR α expression levels [79] and RXR antagonists prevent rexinoid activity [78]. Likewise, the synergy between rexinoids and protein kinase A activators to induce differentiation of atRA-resistant leukemia cells requires transactivation of the RAR-RXR heterodimer [60,83]. Gene expression analyses have demonstrated that LGD1069 **37** (Figure 6) induces adipocyte-specific changes in regressing rat tumors [84] and affects expression of several genes involved in cell growth, including cyclin D1, cox-2, PTEN, and p27 in mammary epithelial cells [85]. This correlated with inhibition of DNA synthesis in S

phase [79] and G1 arrest [81]. All together, these studies suggest that the differentiation activity and cell cycle effects contribute to the chemopreventive activity of previously known rexinoids. In contrast, induction of apoptosis might be the primary effect of the rexinoid AdArs described here, at least in the case of **29**, which exhibits substantial antiproliferative activity against most cancer cell lines evaluated (see Figure 2 and table 1), but reduced RXR transactivating capacity. Whether these rexinoid AdArs cause cell death via activation of RXRs, similar to other previously characterized rexinoids, or the induction of apoptosis is intrinsic to the AdAr structure and independent of RXR transactivation remains to be elucidated.

5. CONCLUSION

In this study, we intended to eliminate RAR binding and transactivation activity in AdArs while maintaining their growth inhibitory and apoptosis inducing profiles. While this goal was accomplished, we also found that some of the AdArs elicited significant RXR α transactivation activity. RXR plays an important role in the anticancer activity of other known rexinoids, which contrasts with the RAR-independence demonstrated in the induction of apoptosis by parent AdArs. Among the four AdArs with RXR activity reported here, only compound **29** was found to have substantial anticancer activity against various types of cancer cells, which paralleled the induction of apoptosis. Interestingly, compound **29** was a partial agonist of RXR α , whereas other AdArs with enhanced RXR transactivation activity elicited limited growth inhibitory effects. Therefore, future studies will be essential to elucidate the role of RXRs on the anticancer activity of rexinoid AdArs.

6. Experimental Protocols

6.1. Chemistry

Solvents were dried according to published methods and distilled before use. HPLC grade solvents were used for the HPLC purification. All other reagents were commercial compounds of the highest purity available. All reactions were carried out under argon atmosphere, and those not involving aqueous reagents were carried out in oven-dried glassware. Analytical thin layer chromatography (TLC) was performed on aluminium plates with Merck Kieselgel 60F254 and visualized by UV irradiation (254 nm) or by staining with an ethanolic solution of phosphomolibdic acid. Flash column chromatography was carried out using Merck Kieselgel 60 (230–400 mesh) under pressure. Infrared spectra were obtained on JASCO FTIR 4200 spectrophotometer, from a thin film deposited onto a NaCl glass. ^1H NMR spectra were recorded in CDCl_3 , CD_2Cl_2 , and CD_3OD at ambient temperature on a Bruker AMX-400 spectrometer at 400 MHz with residual protic solvent as the internal reference [CDCl_3 , $\delta_{\text{H}} = 7.26$ ppm; CD_2Cl_2 , $\delta_{\text{H}} = 5.30$ ppm; CD_3OD , $\delta_{\text{H}} = 3.31$ ppm]; chemical shifts (δ) are given in parts per million (ppm), and coupling constants (J) are given in Hertz (Hz). The proton spectra are reported as follows: δ (multiplicity, coupling constant J , number of protons, assignment). ^{13}C NMR spectra were recorded in CDCl_3 and CD_2Cl_2 or CD_3OD at ambient temperature on the same spectrometer at 100 MHz, with the central peak of CDCl_3 ($\delta_{\text{C}} = 77.0$ ppm), CD_2Cl_2 ($\delta_{\text{C}} = 54.2$ ppm) or CD_3OD ($\delta_{\text{C}} = 49.05$ ppm) as the internal reference. DEPT135 pulse sequences were used to aid in the assignment of signals in the ^{13}C NMR spectra. Mass Spectra were obtained on a Hewlett-Packard HP59970 instrument operating at 70 eV by electron ionisation. High Resolution Mass Spectra were taken on a VG Autospec M instrument. FAB experiments were performed on a VG AutoSpec instrument, using 3-nitrobenzylalcohol or glycerol as matrices. The microwave reactions were carried out in argon-flushed microwave quartz glass vessels in a CEM model Explorer with maximum power at 300 W. Melting points were measured in a Stuart Scientific apparatus.

2-(Adamant-1-yl)-4-bromo-5-methylphenol (11)—A solution of phenol **10** (1.90 g, 10.39 mmol) in anhydrous dichloromethane (7 mL) was treated with 1-adamantanol (1.60 g,

10.39 mmol) and H_2SO_4 (0.53 mL, 10.39 mmol). After stirring at 25 °C for 2 h, the mixture was neutralized with a 5% NaHCO_3 solution and extracted with CH_2Cl_2 (3x). The organic extracts were washed with NaCl, dried over anhydrous Na_2SO_4 and evaporated to afford phenol **11** (3.30 g, 98%) as a white solid. **$^1\text{H-NMR}$** (400.13 MHz, CDCl_3): δ 7.30 (s, 1H, H6 or H3), 6.54 (s, 1H, H3 or H6), 2.28 (s, 3H, 3x AdCH), 2.07 (s, 9H, 3x AdCH₂ + ArCH₃), 1.77 (s, 6H, 3x AdCH₂) ppm.

2-(Adamant-1-yl)-(4-bromo-5-methylphenyl) *tert*-Butyldimethylsilyl Ether (12)—

To a solution of phenol **11** (1.20 g, 3.73 mmol) in DMF (5 mL) were added Et_3N (0.76 mL, 5.04 mmol), DMAP (0.02 g, 0.19 mmol) and TBDMSCl (0.76 g, 5.04 mmol). After stirring for 16 h at room temperature, the mixture was poured into ice-water and extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried over anhydrous Na_2SO_4 and evaporated. The residue was purified by column chromatography on silica gel (100% hexane) to afford bromide **12** (1.40 g, 88%) as a white solid. **$^1\text{H-NMR}$** (400.13 MHz, CDCl_3): δ 7.35 (s, 1H, H6 or H3), 6.71 (s, 1H, H3 or H6), 2.32 (s, 3H, 3x AdCH), 2.10 (s, 9H, 3x AdCH₂ + ArCH₃), 1.79 (s, 6H, 3x AdCH₂), 1.08 (s, 9H, SiC(CH₃)₃), 0.34 (s, 6H, Si(CH₃)₂) ppm. **$^{13}\text{C-NMR}$** (100.62 MHz, CDCl_3): δ 153.7 (s), 139.2 (s), 135.3 (s), 130.8 (d, C6 or C3), 121.3 (d, C3 or C6), 115.6 (s), 40.3 (t, 3x AdCH₂), 37.0 (t, 3x AdCH₂), 36.6 (s, AdC), 29.0 (d, 3x AdCH), 26.4 (q, 3x SiC(CH₃)₃), 22.4 (q, ArCH₃), 18.9 (s, SiC(CH₃)₃), -3.4 (q, 2x Si(CH₃)₂) ppm. **IR** (NaCl): ν 2972 (m, C-H), 2900 (m, C-H), 1746 (m), 1701 (s), 1684 (m), 1650 (m), 1555 (m), 1538 (s), 1520 (s), 1512 (s), 1455 (m), 1392 (m) cm^{-1} . **MS (EI⁺): *m/z*** (%) 437 ([M+1]⁺ [⁸¹Br], 9), 436 (M⁺ [⁸¹Br], 32), 435 ([M+1]⁺ [⁷⁹Br], 10), 434 (M⁺ [⁷⁹Br], 32), 380 (14), 379 (47), 378 (14), 377 (45), 298 (26), 259 (12), 257 (14), 257 (25), 177 (11), 135 (100), 79 (15), 73 (41). **HRMS**: calcd for $\text{C}_{23}\text{H}_{35}^{79}\text{BrOSi}$, 434.1641 and $\text{C}_{23}\text{H}_{35}\text{OSi}^{81}\text{Br}$, 436.1620; found, 434.1639 and 436.1641.

5-(Adamant-1-yl)-4-(*tert*-butyldimethylsilyloxy)-2-methylphenylboronic Acid (13)—

To a cooled (−78 °C) solution of bromide **12** (1.40 g, 3.19 mmol) in THF (8 mL) was slowly added *n*-BuLi (2.3 mL, 1.5 M in THF, 3.51 mmol) over 10 min. After stirring for 0.5 h tri-isopropyl borate (2.2 mL, 9.58 mmol) was added the resulting mixture was stirred for 2 h at −78 °C and was allowed to warm at room temperature overnight. The reaction was cooled (0 °C) and then was treated with water and a solution of 10% HCl in water. The mixture was extracted with EtOAc (3x), washed with brine, dried over anhydrous Na_2SO_4 and evaporated to afford 0.57 g (63%) of the desired boronic acid **13**, which was used in the Suzuki coupling reactions without further purification due to its instability.

Methyl 2-(3-Chloro-4-hydroxyphenyl)acetate (16) [55]—A suspension of **15** (5.0 g, 26.77 mmol) in MeOH (38.3 mL) and benzene (267.9 mL) was treated with a solution of (trimethylsilyl)diazomethane (17.18 mL, 2M in hexane, 34.83 mmol). After stirring for 1.5 h at 25 °C the solvent was evaporated to afford ester **16** (5.3 g, 98%) as a white solid. **$^1\text{H-NMR}$** (400.13 MHz, CDCl_3): δ 6.97 (d, J = 8.2 Hz, 1H, ArH) 6.85 (d, J = 8.2 Hz, 1H, ArH), 5.43 (s, 1H, ArH), 3.64 (s, 3H), 3.48 (s, 2H) ppm.

Methyl 2-(3-Chloro-4-(trifluoromethylsulfonyloxy)phenyl)acetate (17) [86]

General procedure for the synthesis of triflates: To a solution of phenol **16** (0.90 g, 4.44 mmol) and pyridine (1.1 mL) in CH_2Cl_2 (30 mL) was added drop wise trifluoromethanesulfonic anhydride (0.92 mL, 6.84 mmol). The reaction mixture was allowed to warm to room temperature, stirred for 12 h, washed (2 x H_2O , 10% HCl, and brine), dried (Na_2SO_4) and the solvent was removed to afford 1.2 g (82%) of **17** as a white solid (m.p.: 54 °C, CH_2Cl_2 /hexane). **$^1\text{H-NMR}$** (400.13 MHz, CDCl_3): δ 7.57 (d, J = 8.0 Hz, 1H, ArH), 7.23 (d, J = 8.0 Hz, 1H, ArH), 7.10 (s, 1H, H2), 3.71 (s, 3H), 3.63 (s, 2H) ppm.

2-Chloro-4-formylphenyl Trifluoromethanesulfonate (19) [50]—In accordance to general procedure described above, compound **18** (0.1 g, 0.60 mmol) was treated with pyridine (1.1 mL, 2.1 mmol) and trifluoromethanesulfonic anhydride (0.12 mL, 0.74 mmol) to afford **19** (0.14 g, 82%) as a white solid. ¹H-NMR (400.13 MHz, CDCl₃): δ 10.00 (s, 1H, CHO), 8.16 (d, *J* = 1.9 Hz, 1H, H3), 7.88 (dd, *J* = 8.2 Hz, 1.9 Hz, 1H, H6), 7.55 (d, *J* = 8.2 Hz, 1H, H5) ppm.

(E)-Ethyl 3-(3-Chloro-4-(trifluoromethylsulphonyloxy)phenyl)acrylate (20) [43]—To a solution of triethyl 2-phosphonoacetate (0.11 mL, 0.54 mmol) in THF (1.1 mL) was added NaH (0.02 g, 60% in mineral oil, 0.54 mmol) at 0 °C. After stirring for 15 min, a solution of aldehyde **19** (1.60 g, 6.58 mmol) in THF (1.2 mL) was slowly added, via cannula, and the mixture was stirred for 4 h at the same temperature. The mixture was poured into H₂O and extracted with AcOEt (3x). The combined organic extracts were washed with an aqueous saturated NH₄Cl solution (3x) and brine, dried with Na₂SO₄, filtered and concentrated to dryness. The residue was purified by flash chromatography (silica gel, 95:5 hexane/AcOEt) to afford **20** (91 mg, 51% yield) as a white powder. ¹H-NMR (300 MHz, CDCl₃): δ 7.67 (d, *J* = 1.9 Hz, 1H, H2), 7.59 (d, *J* = 16.0 Hz, 1H, CH=CHCO₂Et), 7.48 (dd, *J* = 8.5, 1.8 Hz, 1H, H6), 7.38 (d, *J* = 8.5 Hz, 1H, H5), 6.45 (d, *J* = 16.0 Hz, 1H, CH=CHCO₂Et), 4.28 (q, *J* = 7.1 Hz, 2H, CO₂CH₂CH₃), 1.35 (t, *J* = 7.1 Hz, 3H, CO₂CH₂CH₃) ppm.

Methyl 2-[5'-(Adamant-1-yl)-4'-(tert-butylidimethylsilyloxy)-2-chloro-2'-methylbiphenyl-4-yl]acetate (21)

General procedure for the coupling of aryl triflates with arylboronic acids: A Schlenk tube was charged with triflate **17** (0.05 g, 0.13 mmol), Pd(PPh₃)₄ (0.015 g, 0.013 mmol), arylboronic acid **13** (0.06 g, 0.19 mmol) and Et₃N (0.07 mL, 0.523 mmol) in DMF (0.4 mL). The reaction mixture was thoroughly degassed with three freeze-thaw cycles, placed in a 90 °C oil bath and stirred for 23 h at 90 °C. After cooling down to room temperature, water was added and the mixture was extracted with AcOEt (3x). The combined organic extracts were washed with NH₄Cl, H₂O, brine, dried (Na₂SO₄) and the solvent was evaporated. Purification by column chromatography on silica gel (98:2 hexane/AcOEt) provided **21** (0.05 g, 78%) as a yellow oil. ¹H-NMR (400.13 MHz, CDCl₃): δ 7.39 (s, 1H, H3), 7.22 (br, 2H, H6 + H5), 6.97 (s, 1H, H6' or H3'), 6.70 (s, 1H, H3' or H6'), 3.75 (s, 3H, COOCH₃), 3.65 (s, 2H, CH₂COOCH₃), 2.11 (s, 6H, 3x AdCH₂), 2.06 (s, 6H, 3x AdCH + ArCH₃), 1.77 (br, 6H, 3x AdCH₂), 1.08 (s, 9H, SiC(CH₃)₃), 0.39 (s, 6H, Si(CH₃)₂) ppm. ¹³C-NMR (100.62 MHz, CDCl₃): δ 171.5 (s, C=O), 154.0 (s), 139.7 (s), 136.5 (s), 134.0 (s, 2x), 133.8 (s), 131.8 (d), 130.9 (s), 130.0 (d), 128.6 (d), 127.3 (d), 120.1 (d), 52.2 (q, CH₂COOCH₃), 40.6 (t, 3x AdCH₂), 40.4 (t, CH₂COOCH₃), 37.0 (t, 3x AdCH₂), 36.5 (s, AdC), 29.0 (d, 3x AdCH), 26.4 (q, 3x, SiC(CH₃)₃), 19.4 (q, ArCH₃), 18.9 (s, SiC(CH₃)₃), -3.3 (q, SiCH₃), -3.4 (q, SiCH₃) ppm. IR (NaCl): ν 2902 (s, C-H), 2851 (m, C-H), 1740 (m, C=O), 1715 (m), 1484 (m), 1452 (m), 1391 (m), 1252 (s), 1227 (m), 1151 (m), 1018 (m), 837 (s), 779 (s) cm⁻¹. MS (EI⁺): *m/z* (%) 541 ([M+1]⁺ [³⁷Cl], 16), 540 (M⁺ [³⁷Cl], 46), 539 ([M+1]⁺ [³⁵Cl], 43), 538 (M⁺ [³⁵Cl], 100), 483 (34), 482 (33), 481 (80), 459 (21), 299 (28), 242 (23), (23), 135 (45). HRMS: calcd for C₃₂H₄₃³⁵ClO₃Si, 538.2670 and C₃₂H₄₃³⁷ClO₃Si, 540.2641; found, 538.2676 and 540.2653.

Methyl 2-[(5'-(Adamant-1-yl)-2-chloro-4'-hydroxy-2'-methylbiphenyl-4-yl]acetate (22)

General procedure for the cleavage of silyl ethers: To a stirred solution of **21** (0.12 g, 0.22 mmol) in THF (0.21 mL) was added drop wise tetrabutylammonium fluoride (0.25 mL, 1M in THF, 0.25 mmol) at 0 °C and the mixture was stirred for 2.5 h at 0 °C. The solvent was removed in vacuo and the residue was purified by column chromatography on silica gel (50:50 hexane/AcOEt) to afford 0.09 g (94%) of **22** as a yellow oil. ¹H-NMR (400.13 MHz, CDCl₃): δ 7.39

(s, 1H, H3), 7.20 (br, 2H, H6 + H5), 6.95 (s, 1H, H6' or H3'), 6.57 (s, 1H, H3' or H6'), 3.75 (s, 3H, CO₂CH₃), 3.66 (s, 2H, CH₂CO₂CH₃), 2.11 (s, 6H, 3x AdCH₂), 2.06 (s, 3H, ArCH₃ or 3x AdCH), 2.04 (s, 3H, 3x AdCH or ArCH₃), 1.77 (br, 6H, 3x AdCH₂) ppm. **¹³C-NMR** (100.62 MHz, CDCl₃): δ 172.1 (s, COOMe), 153.9 (s), 139.6 (s), 134.6 (s, 2x), 133.9 (s, 2x), 133.5 (s), 131.8 (d), 131.2 (s), 130.0 (d), 128.6 (d), 127.4 (d), 117.9 (d), 52.2 (q, CH₂COOCH₃), 40.7 (t, 3x AdCH₂ + CH₂COOCH₃), 37.0 (t, 3x AdCH₂), 36.4 (s, AdC), 29.0 (d, 3x AdCH), 19.1 (q, ArCH₃) ppm. **IR** (NaCl): ν 3100–2700 (br, O-H), 2901 (s, C-H), 2848 (m, C-H), 1716 (s, C=O), 1437 (m), 1397 (s), 1258 (s), 1219 (s), 1144 (s), 1011 (m), 850 (s), 832 (s) cm⁻¹. **MS (EI⁺)**: *m/z* (%) 427 ([M+1]⁺ [³⁷Cl], 2), 426 (M⁺ [³⁷Cl], 38), 425 ([M+1]⁺ [³⁵Cl], 31), 424 (M⁺ [³⁵Cl], 100), 367 (19), 330 (11).

Methyl 2-[5'-(Adamant-1-yl)-2-chloro-4'-[(2-methoxyethoxy)methoxy]-2'-methylbiphenyl-4-yl]acetate (23)

General procedure for the protection of phenols with MEMCl: To a cooled (0 °C) suspension of **22** (0.12 g, 0.22 mmol) in DMF (1.5 mL) under Ar was added NaH (0.004 g, 60% in mineral oil, 0.10 mmol). After 0.5 h at 0 °C MEMCl (0.011 mL, 0.10 mmol) was added drop wise. The reaction mixture was stirred for 4 h at room temperature, and was extracted with ethyl acetate (3x). The combined organic extracts were washed with brine, dried (Na₂SO₄) and evaporated. The residue was subjected to column chromatography on silica gel (50:50 hexane/CH₂Cl₂) to afford **23** (0.072 g, 64%) as a yellow oil. **¹H-NMR** (400.13 MHz, CD₂Cl₂): δ 7.39 (s, 1H, H3), 7.19 (br, 2H, H6 + H5), 7.04 (s, 1H, H6' or H3'), 6.96 (s, 1H, H3' or H6'), 5.37 (d, *J* = 6.6 Hz, 1H, OCH₂O), 5.33 (d, *J* = 6.6 Hz, 1H, OCH₂O), 3.90 (t, *J* = 4.6 Hz, 2H, OCH₂O(CH₂)₂OCH₃), 3.74 (s, 3H, COOCH₃), 3.6–3.5 (m, 4H, OCH₂O(CH₂)₂OCH₃ + CH₂COOMe), 3.42 (s, 3H, OCH₂O(CH₂)₂OCH₃), 2.08 (s, 9H, ArCH₃ or 3x AdCH + 3x AdCH₂), 2.04 (s, 3H, 3x AdCH or ArCH₃), 1.75 (br, 6H, 3x AdCH₂) ppm. **¹³C-NMR** (100.62 MHz, CD₂Cl₂): δ 171.5 (s, CO₂Me), 156.0 (s), 139.7 (s), 135.7 (s), 134.7 (s), 134.2 (s), 133.8 (s), 132.0 (s), 131.7 (d), 130.1 (d), 128.2 (d), 127.4 (d), 115.7 (d), 93.5 (t, OCH₂O(CH₂)₂OCH₃), 71.7 (t, OCH₂O(CH₂)₂OCH₃), 67.8 (t, OCH₂O(CH₂)₂OCH₃), 59.0 (q, OCH₂O(CH₂)₂OCH₃), 52.2 (q, ArCH₂COOCH₃), 40.9 (t, 3x AdCH₂), 40.4 (t, ArCH₂COOCH₃), 37.1 (t, 3x AdCH₂), 36.8 (s, AdC), 29.1 (d, 3x AdCH), 19.5 (q, ArCH₃) ppm. **IR** (NaCl): ν 2904 (s, C-H), 2851 (s, C-H), 1741 (s, C=O), 1605 (d), 1485 (m), 1450 (m), 1252 (m), 1217 (m), 1155 (s), 1102 (s), 1014 (s) cm⁻¹. **MS (EI⁺)**: *m/z* (%) 515 ([M+1]⁺ [³⁷Cl], 1), 514 (M⁺ [³⁷Cl], 2), 513 ([M+1]⁺ [³⁵Cl], 22), 512 (M⁺ [³⁵Cl], 22), 438 (11), 436 (24), 303 (10), 89 ([C₄H₉O₂], 100). **HRMS**: calcd for C₃₀H₃₇³⁵ClO₅, 512.2330 and C₃₀H₃₇³⁷ClO₅, 514.2300; found, 521.2330 and 514.2303.

2-[5'-(Adamant-1-yl)-2-chloro-4'-[(2-methoxyethoxy)methoxy]-2'-methylbiphenyl-4-yl]acetic Acid (24)

General procedure for hydrolysis of esters: To a stirred suspension of **23** (0.02 mg, 0.03 mmol) in MeOH (0.5 mL) was added Na₂CO₃ (0.14 mL, 2M in H₂O, 0.28 mmol). The mixture was stirred at 70 °C for 3 h, cooled down to room temperature, acidified (10% HCl), and extracted with EtOAc. The combined organic extracts were washed (H₂O, brine), dried (Na₂SO₄), and evaporated. The residue was purified by column chromatography on silica gel (95:5 CH₂Cl₂/MeOH) to provide 12 mg (64%) of **24** as a colourless oil. **¹H-NMR** (400.13 MHz, CD₂Cl₂): δ 7.40 (d, *J* = 8.0 Hz, 1.4 Hz, 1H, H3), 7.24 (d, *J* = 8.0 Hz, 1.4 Hz, 1H, H5), 7.20 (d, *J* = 8 Hz, 1H, H6), 7.01 (s, 1H, H6' or H3'), 6.95 (s, 1H, H3' or H6'), 5.32 (s, 2H, OCH₂O), 3.8–3.9 (m, 2H, O(CH₂)₂O), 3.70 (s, 2H, CH₂COOH), 3.5–3.6 (m, 2H, OCH₂O(CH₂)₂OCH₃), 3.36 (s, 3H, OCH₃), 2.07 (m, 12H, 3x AdCH + ArCH₃ + 3x AdCH₂), 1.76 (br, 6H, 3x AdCH₂) ppm. **¹³C-NMR** (100.62 MHz, CD₂Cl₂): δ 175.2 (s, COOH), 156.6 (s), 140.3 (s), 135.3 (s), 134.7 (s), 134.2 (s), 132.5 (s), 132.4 (d), 130.7 (d), 128.7 (d), 128.3 (d), 116.3 (d), 94.0 (t, OCH₂O(CH₂)₂OCH₃), 136.4 (s), 72.2 (t, OCH₂O(CH₂)₂OCH₃), 68.7 (t, OCH₂O(CH₂)₂OCH₃), 59.2 (q, OCH₂O(CH₂)₂OCH₃), 41.4 (t, ArCH₂COOCH₃ + 3x AdCH₂), 37.6

(t, 3x AdCH₂), 37.3 (s, AdC), 29.8 (d, 3x AdCH), 19.8 (q, ArCH₃) ppm. **IR** (NaCl): ν 3400–2500 (br, O-H), 2905 (s, C-H), 2851 (s, C-H), 1713 (s, C=O), 1604 (m), 1485 (s), 1452 (s), 1260 (s), 1215 (s), 1100 (s), 1017 (s) cm⁻¹. **MS** (**EI**⁺): m/z (%) 501 ([M+1]⁺ [³⁷Cl], 2), 500 (M⁺ [³⁷Cl], 7), 499 ([M+1]⁺ [³⁵Cl], 6), 498 (M⁺ [³⁵Cl], 18), 424 (10), 422 (23), 89 ([C₄H₉O₂], 100). **HRMS**: calcd for C₂₉H₃₅³⁵ClO₅, 498.2173 and C₂₉H₃₅³⁷ClO₅, 500.2144; found, 498.2178 and 500.2145.

2-[5'-(Adamant-1-yl)-2-chloro-4'-hydroxy-2'-methylbiphenyl-4-yl]acetic Acid

(25)—According to general procedure for hydrolysis of esters, treatment of compound **22** (0.02 g, 0.05 mmol) with Na₂CO₃ (0.24 mL, 2M in H₂O, 0.48 mmol) for 3 h at 70 °C afforded, after purification by column chromatography on silica gel (95:5 CH₂Cl₂/MeOH), 11 mg (54%) of **25** as a white solid. **¹H-NMR** (400.13 MHz, CDCl₃): δ 7.40 (s, 1H, H₃), 7.21 (br, 2H, H₆ + H₅), 6.94 (s, 1H, H₆' or H₃'), 6.58 (s, 1H, H₃' or H₆'), 3.68 (s, 2H, CH₂COOH), 2.10 (s, 6H, 3x AdCH₂), 2.05 (s, 3H, ArCH₃ or 3x AdCH), 2.03 (s, 3H, 3x AdCH or ArCH₃), 1.75 (br, 6H, 3x AdCH₂) ppm. **¹³C-NMR** (100.62 MHz, CDCl₃): δ 176.2 (s, CO₂H), 153.9 (s), 139.8 (s, ArC), 134.7 (s), 134.0 (s), 133.6 (s), 133.6 (s), 131.8 (d), 131.3 (s), 130.2 (d), 128.6 (d), 127.5 (d), 118.0 (s), 118.0 (d), 40.7 (t, 3x AdCH₂), 40.3 (t, CH₂COOH), 37.0 (t, 3x AdCH₂), 36.4 (s, AdC), 29.0 (d, 3x AdCH), 19.1 (q, ArCH₃) ppm. **IR** (NaCl): ν 3100–2700 (br, O-H), 2898 (m, C-H), 2847 (s, C-H), 1691 (s, C=O), 1417 (m), 1398 (s), 1292 (m), 1223 (m), 1146 (s), 1067 (m), 894 (m), 877 (s), 825 (m), 668 (m) cm⁻¹. **MS** (**EI**⁺): m/z (%) 413 ([M+1]⁺ [³⁷Cl], 12), 412 (M⁺ [³⁷Cl], 40), 411 ([M+1]⁺ [³⁵Cl], 34), 410 (M⁺ [³⁵Cl], 100), 355 (10), 353 (25), 316 (13). **HRMS**: calcd for C₂₅H₂₇³⁵ClO₃, 410.1649 and C₂₅H₂₇³⁷ClO₃, 412.1619; found, 410.1630 and 412.1625.

Ethyl 6-[5-(Adamant-1-yl)-4-(tert-butyldimethylsilyloxy)-2-methylphenyl]-5-chloro-2-naphthoate

(26)—In accordance with the general procedure for the coupling of aryl triflates with arylboronic acids, the reaction of triflate **14** (0.05 g, 0.13 mmol) with arylboronic acid **13** (0.06 g, 0.19 mmol) gave, after purification by column chromatography on silica gel (98:2 hexane/AcOEt), 0.06 g (85%) of **26** as a white solid (m.p.: 177 °C, CH₂Cl₂/hexane). **¹H-NMR** (400.13 MHz, CDCl₃): δ 8.66 (s, 1H, H₁), 8.44 (d, J = 8.8 Hz, 1H, ArH) 8.22 (d, J = 8.8 Hz, 1H, ArH), 7.90 (d, J = 8.4 Hz, 1H, ArH), 7.47 (d, J = 8.4 Hz, 1H, ArH), 7.10 (s, 1H, H₆' or H₃'), 6.79 (s, 1H, H₃' or H₆'), 4.50 (q, J = 7.0 Hz, 2H, CO₂CH₂CH₃), 2.16 (s, 6H, 3x AdCH₂), 2.10 (s, 3H, ArCH₃ or 3x AdCH), 2.08 (s, 3H, 3x AdCH or ArCH₃), 1.79 (br, 6H, 3x AdCH₂), 1.50 (t, J = 7.0 Hz, 3H, CO₂CH₂CH₃), 1.13 (s, 9H, SiC(CH₃)₃), 0.44 (s, 6H, Si(CH₃)₂) ppm. **¹³C-NMR** (100.62 MHz, CDCl₃): δ 166.4 (s, CO₂Et), 154.2 (s), 140.8 (s), 136.7 (s), 133.8 (s), 133.2 (s), 132.6 (s), 131.6 (s), 130.8 (d), 130.7 (s), 129.9 (d), 128.4 (d), 128.1 (s), 127.5 (d), 126.4 (d), 125.2 (d), 120.2 (d), 61.2 (t, COOCH₂CH₃), 40.5 (t, 3x AdCH₂), 37.0 (t, 3x AdCH₂), 36.6 (s, AdC), 29.0 (d, 3x AdCH), 26.4 (q, 3x SiC(CH₃)₃), 19.5 (q, ArCH₃), 18.9 (s, SiC(CH₃)₃), 14.4 (q, COOCH₂CH₃), -3.3 (q, SiCH₃), -3.4 (q, Si(CH₃)₂) ppm. **IR** (NaCl): ν 2902 (m, C-H), 2850 (m, C-H), 1711 (m, C=O), 1246 (s), 1192 (m), 1097 (m), 977 (m), 885 (m), 837 (s), 778 (s), 753 (m) cm⁻¹. **MS** (**EI**⁺): m/z (%) 591 ([M+1]⁺ [³⁷Cl], 17), 590 (M⁺ [³⁷Cl], 46), 589 ([M+1]⁺ [³⁵Cl], 46), 588 (M⁺ [³⁵Cl], 100), 534 (13), 533 (34), 532 (34), 531 (75), 411 (20), 409 (22), 135 (48). **HRMS**: calcd for C₃₆H₄₅³⁵ClO₃Si, 588.2827 and C₃₆H₄₅³⁷ClO₃Si, 590.2797; found, 588.2831 and 590.2819.

Ethyl 6-[5-(Adamant-1-yl)-4-hydroxy-2-methylphenyl]-5-chloro-2-naphthoate

(27)—According to the general procedure for the cleavage of the silyl ether group, treatment of compound **26** (0.14 g, 0.23 mmol) with a solution of TBAF (0.25 mL, 1M in THF, 0.25 mmol) afforded, after purification by column chromatography on silica gel (50:50 hexane/AcOEt), 0.07 g (68%) of **27** as a white solid (m.p.: 201 °C, CH₂Cl₂/hexane). **¹H-NMR** (400.13 MHz, CDCl₃): δ 8.34 (s, 1H, H₁), 8.10 (d, J = 8.8 Hz, 1H, ArH), 7.89 (d, J = 8.8 Hz, 1H, ArH),

7.58 (d, $J = 8.0$ Hz, 1H, ArH), 7.12 (d, $J = 8.0$ Hz, 1H, ArH), 6.74 (s, 1H, H6' or H3'), 6.35 (s, 1H, H3' or H6'), 4.18 (q, $J = 7.1$ Hz, 2H, CO₂CH₂CH₃), 1.84 (s, 6H, 3x AdCH₂), 1.74 (s, 6H, ArCH₃ or 3x AdCH), 1.46 (br, 6H, 3x AdCH₂), 1.18 (t, $J = 7.1$ Hz, 3H, CO₂CH₂CH₃) ppm. **¹³C-NMR** (100.62 MHz, CDCl₃): δ 166.7 (s, C=O₂Et), 154.2 (s), 140.7 (s), 134.4 (s), 133.8 (s), 132.6 (s), 131.7 (s), 131.0 (d), 130.8 (s), 129.8 (d), 128.3 (d), 128.0 (s), 127.7 (d), 126.5 (d), 125.2 (d), 118.2 (d), 61.4 (t, COOCH₂CH₃), 40.7 (t, 3x AdCH₂), 37.0 (t, 3x AdCH₂), 36.4 (s, AdC), 29.0 (d, 3x AdCH), 19.1 (q, ArCH₃), 14.3 (q, COOCH₂CH₃) ppm. **IR** (NaCl): ν 3400–3100 (br, O-H), 2901 (s, C-H), 2849 (m, C-H), 1682 (s, C=O), 1609 (w), 1471 (w), 1402 (m), 1359 (m), 1293 (s), 1227 (s), 1149 (s), 1101 (s), 819 (s), 749 (s) cm⁻¹. **MS (EI⁺)**: m/z (%) 477 ([M+1]⁺ [³⁷Cl], 12), 476 (M⁺ [³⁷Cl], 40), 475 ([M+1]⁺ [³⁵Cl], 36), 474 (M⁺ [³⁵Cl], 100), 440 (27), 417 (13). **HRMS**: calcd for C₃₀H₃₁³⁵ClO₃, 474.1962 and C₃₀H₃₁³⁷ClO₃, 476.1932; found, 474.1947 and 476.1931.

Ethyl 6-[5-(Adamant-1-yl)-4-[(2-methoxyethoxy)methoxy]-2-methylphenyl]-5-chloro-2-naphthoate (28)—According to the general procedure for the protection of phenols with MEMCl, compound **27** (0.02 g, 0.05 mmol) was treated with NaH (0.002 g, 60% in mineral oil, 0.05 mmol) and MEMCl (0.010 mL, 0.05 mmol) to afford, after purification by column chromatography on silica gel (50:50 hexane/CH₂Cl₂), 0.012 g (46%) of **28** as a colourless oil. **¹H-NMR** (400.13 MHz, CDCl₃): δ 8.65 (s, 1H, H1), 8.43 (d, $J = 8.8$ Hz, 1H, ArH), 8.21 (d, $J = 8.8$ Hz, 1H, ArH), 7.90 (d, $J = 8.4$ Hz, 1H, ArH), 7.43 (d, $J = 8.4$ Hz, 1H, ArH), 7.12 (s, 1H, H6' or H3'), 7.07 (s, 1H, H3' or H6'), 5.43 (d, $J = 7.0$ Hz, 1H, OCH₂O), 5.38 (d, $J = 7.0$ Hz, 1H, OCH₂O), 4.89 (q, $J = 6.9$ Hz, 2H, COOCH₂CH₃), 3.94 (t, $J = 4.4$ Hz, 2H, OCH₂O(CH₂)₂OCH₃), 3.67 (t, $J = 4.4$ Hz, 2H, OCH₂O(CH₂)₂OCH₃), 3.45 (s, 3H, OCH₂O(CH₂)₂OCH₃), 2.13 (s, 6H, 3x AdCH₂), 2.12 (s, 3H ArCH₃ or 3 x AdCH), 2.07 (s, 3H, 3x AdCH or ArCH₃), 1.78 (br, 6H, 3x AdCH₂), 1.49 (t, $J = 6.9$ Hz, 3H, COOCH₂CH₃) ppm. **¹³C-NMR** (100.62 MHz, CDCl₃): δ 166.5 (s, C=O₂Et), 156.2 (s), 140.7 (s), 135.9 (s), 134.6 (s), 133.3 (s), 132.7 (s), 132.8 (s), 130.9 (d), 130.7 (s), 129.8 (d), 128.3 (s), 128.0 (d), 127.7 (d), 126.6 (d), 125.3 (d), 115.9 (d), 93.5 (t, OCH₂O(CH₂)₂OCH₃), 71.7 (t, OCH₂), 67.9 (t, OCH₂), 61.3 (t, OCH₂), 59.1 (q, OCH₂O(CH₂)₂OCH₃), 40.9 (t, 3x AdCH₂), 37.1 (t, 3x AdCH₂), 36.9 (s, AdC), 29.1 (d, 3x AdCH), 19.6 (q, ArCH₃), 14.4 (q, COOCH₂CH₃) ppm. **IR** (NaCl): ν 2961 (m, C-H), 2902 (m, C-H), 2849 (m, C-H), 1691 (m, C=O), 1257 (s), 1084 (s), 1013 (s), 793 (s) cm⁻¹. **MS (EI⁺)**: m/z (%) 565 ([M + 1]⁺ [³⁷Cl], 3), 564 (M⁺ [³⁷Cl], 9), 563 ([M + 1]⁺ [³⁵Cl], 9), 562 (M⁺ [³⁵Cl], 23), 489 ([M - C₂H₅O₂]⁺ [³⁵Cl], 21), 89 ([C₄H₉O₂]⁺, 100). **HRMS**: calcd for C₃₄H₃₉³⁵ClO₅, 562.2486 and C₃₄H₃₉³⁷ClO₅, 564.2457; found, 562.2475 and 564.2469.

6-[5-(Adamant-1-yl)-4-[(2-methoxyethoxy)methoxy]-2-methylphenyl]-5-chloro-2-naphthoic Acid (29)—According to general procedure for hydrolysis of esters, treatment of compound **28** (0.01g, 0.02 mmol) with Na₂CO₃ for 3 h at 70 °C afforded, after purification, 6 mg (57%) of **29** as a colourless oil. **¹H-NMR** (400.13 MHz, CD₂Cl₂): δ 8.67 (s, 1H, H1), 8.38 (d, $J = 8.8$ Hz, 1H, ArH), 8.38 (d, $J = 8.8$ Hz, 1H, ArH), 8.16 (dd, $J = 8.8$, 1.6 Hz, 1H, ArH), 7.89 (d, $J = 8.2$ Hz, 1H, ArH), 7.37 (d, $J = 8.2$ Hz, 1H, ArH), 7.00 (s, 1H, H6' or H3'), 6.98 (s, 1H, H3' or H6'), 5.30 (d, $J = 6.7$ Hz, 1H, OCH₂O), 5.26 (d, $J = 6.7$ Hz, 1H, OCH₂O), 3.81 (m, 2H, OCH₂O(CH₂)₂OCH₃), 3.53 (m, 2H, OCH₂O(CH₂)₂OCH₃), 3.30 (s, 3H, OCH₂O(CH₂)₂OCH₃), 2.04 (s, 6H, 3x AdCH₂), 2.01 (s, 3H, ArCH₃ or 3x AdCH), 1.97 (s, 3H, 3x AdCH or ArCH₃), 1.69 (s, 6H, 3x AdCH₂) ppm. **¹³C-NMR** (100.62 MHz, CD₂Cl₂): δ 170.7 (s, C=O₂H), 156.5 (s), 141.6 (s), 136.4 (s), 135.0 (s), 133.9 (s), 133.2 (s), 133.1 (s), 132.9 (s), 132.2 (d), 131.0 (s), 130.4 (d), 128.3 (d), 128.2 (d), 127.1 (s), 125.7 (d), 116.2 (d), 93.8 (t, OCH₂O), 72.1 (t, OCH₂), 68.5 (t, OCH₂), 59.1 (q, OCH₃), 41.2 (t, 3x AdCH₂), 37.4 (t, 3x AdCH₂), 37.2 (s, AdC), 29.6 (d, 3x AdCH), 19.7 (q, ArCH₃) ppm. **IR** (NaCl): ν 3500–2500 (br, O-H), 2962 (s, C-H), 2905 (s, C-H), 2851 (m, C-H), 1693 (m, C=O), 1472 (w), 1414 (w), 1260 (s), 1096 (s), 1018 (s), 800 (s) cm⁻¹. **MS (EI⁺)**: m/z (%) 537 ([M + 1]⁺ [³⁷Cl],

2), 536 (M^+ [^{37}Cl], 6), 535 ($[M + 1]^+$ [^{35}Cl], 6), 534 (M^+ [^{35}Cl], 15), 485 (13), 89 ($[\text{C}_4\text{H}_9\text{O}_2]^+$, 100). **HRMS**: calcd for $\text{C}_{32}\text{H}_{35}^{35}\text{ClO}_5$, 534.2173 and $\text{C}_{32}\text{H}_{35}^{37}\text{ClO}_5$, 536.2144; found, 534.2164 and 536.2170.

6-[5-(Adamant-1-yl)-4-hydroxy-2-methylphenyl]-5-chloro-2-naphthoic Acid (30)

—According to general procedure for hydrolysis of esters, the treatment of compound **27** (0.04 g, 0.09 mmol) with Na_2CO_3 for 3 h at 70 °C afforded, after purification, 0.034 g (85%) of **30** as a white solid (m.p.: 236 °C, CH_2Cl_2 /hexane). **$^1\text{H-NMR}$** (400.13 MHz, CDCl_3): δ 8.76 (s, 1H, H1), 8.47 (d, J = 8.8 Hz, 1H, ArH), 8.27 (d, J = 8.8 Hz, 1H, ArH), 7.93 (d, J = 8.4 Hz, 1H, ArH), 7.46 (d, J = 8.4 Hz, 1H, ArH), 7.06 (s, 1H, H6' or H3'), 6.64 (s, 1H, H3' or H6'), 2.15 (s, 6H, 3x AdCH₂), 2.07 (s, 6H, 3x AdCH + ArCH₃), 1.78 (br, 6H, 3x AdCH₂) ppm. **$^{13}\text{C-NMR}$** (100.62 MHz, CDCl_3): δ 171.7 (s, CO₂H), 154.0 (s), 141.2 (s), 134.5 (s), 133.9 (s), 132.7 (s), 132.1 (d), 131.9 (s), 130.0 (d), 128.4 (d), 127.9 (d), 127.0 (s), 126.7 (d), 125.5 (d), 118.1 (d), 40.8 (t, 3x AdCH₂), 37.0 (t, 3x AdCH₂), 36.5 (s, AdC), 29.0 (d, 3x AdCH), 19.1 (q, ArCH₃) ppm. **IR** (NaCl): ν 3200–2500 (br, O-H), 2967 (m, C-H), 2901 (s, C-H), 2850 (m, C-H), 1698 (s, C=O), 1540 (s), 1509 (s), 1472 (m), 1456 (m), 1292 (s), 1253 (s), 1220 (m), 975 (m), 842 (m), 818 (m), 154 (m) cm^{-1} . **MS** (EI^+): m/z (%) 449 ($[M+1]^+$ [^{37}Cl], 11), 448 (M^+ [^{37}Cl], 36), 477 ($[M+1]^+$ [^{35}Cl], 30), 446 (M^+ [^{35}Cl], 100), 389 (20), 352 (11). **HRMS**: calcd for $\text{C}_{28}\text{H}_{27}^{35}\text{ClO}_3$, 446.1649 and $\text{C}_{28}\text{H}_{27}^{37}\text{ClO}_3$, 448.1619; found, 446.1645 and 448.1626.

(E)-Ethyl 3-[5'-(Adamant-1-yl)-4'-(tert-butylidimethylsilyloxy)-2-chloro-2'-methylbiphenyl-4-yl]acrylate (31)—To a mixture of triflate **20** (0.10 g, 0.27 mmol) and $\text{Pd}(\text{PPh}_3)_4$ (0.03 g, 0.03 mmol) in DMF (2.2 mL) in a Schlenk flask was added arylboronic acid **13** (0.10 g, 0.25 mmol), Na_2CO_3 (0.25 mL, 0.50 mmol) and LiCl (0.02 g, 0.56 mmol). The reaction mixture was stirred for 22 h at 80 °C. After cooling down to room temperature, water was added and the mixture was extracted with EtOAc (3x). The combined organic

extracts were washed with NH_4Cl , H_2O and brine, dried (Na_2SO_4) and evaporated. The residue was subjected to column chromatography (C_{18} - SiO_2 , CH_3CN) to afford **31** (0.10 g, 67%) as a yellow oil. **$^1\text{H-NMR}$** (400.13 MHz, CDCl_3): δ 7.67 (d, J = 16.0 Hz, 1H, H3), 7.69 (s, 1H, H3), 7.43 (d, J = 8.0 Hz, 1H, H5 or H6), 7.28 (d, J = 8.0 Hz, 1H, H6 or H5), 6.97 (s, 1H, H6'), 6.71 (s, 1H, H3'), 6.48 (d, J = 16.0 Hz, 1H, H2), 4.29 (q, J = 7.2 Hz, 2H, $\text{COOCH}_2\text{CH}_3$), 2.12 (s, 6H, 3x AdCH₂), 2.07 (s, 6H, 3x AdCH + ArCH₃), 1.77 (br, 6H, 3x AdCH₂), 1.36 (t, J = 7.2 Hz, 3H, $\text{COOCH}_2\text{CH}_3$), 1.09 (s, 9H, $\text{SiC}(\text{CH}_3)_3$), 0.40 (s, 6H, $\text{Si}(\text{CH}_3)_2$) ppm. **$^{13}\text{C-NMR}$** (100.62 MHz, CDCl_3): δ 166.7 (s, CO_2Et), 154.3 (s), 142.9 (d), 142.8 (s), 136.7 (s), 134.6 (s), 134.5 (s), 133.9 (s), 132.2 (d), 130.6 (s), 128.7 (d), 128.4 (d), 125.9 (d), 120.3 (d), 119.2 (d), 60.6 (q, $\text{COOCH}_2\text{CH}_3$), 40.6 (t, 3x AdCH₂), 37.0 (t, 3x AdCH₂), 36.6 (s, AdC), 29.0 (d, 3x AdCH), 26.4 (d, 3x $\text{SiC}(\text{CH}_3)_3$), 19.4 (q, ArCH₃), 18.9 (s, $\text{SiC}(\text{CH}_3)_3$), 14.3 (q, $\text{COOCH}_2\text{CH}_3$), -3.3 (q, SiCH_3), -3.4 (q, SiCH_3) ppm. **IR** (NaCl): ν 2902 (s, C-H), 2852 (m, C-H), 1713 (s, C=O), 1484 (m), 1453 (m), 1305 (m), 1254 (s), 1173 (s), 1152 (s), 872 (s), 835 (s), 779 (s) cm^{-1} . **MS** (EI^+): m/z (%) 557 ($[M+1]^+$ [^{37}Cl], 16), 566 (M^+ [^{37}Cl], 44), 565 ($[M+1]^+$ [^{35}Cl], 43), 564 (M^+ [^{35}Cl], 100), 510 (14), 509 (37), 508 (36), 507 (84), 387 (26), 385 (25), 299 (19), 135 (62). **HRMS**: calcd for $\text{C}_{34}\text{H}_{45}^{35}\text{ClO}_3$, 564.2827 and $\text{C}_{34}\text{H}_{45}^{37}\text{ClO}_3$, 566.2797; found, 564.2869 and 566.2820.

(E)-Ethyl 3-[5'-(Adamant-1-yl)-2-chloro-4'-hydroxy-2'-methylbiphenyl-4-yl]acrylate (32)

—In accordance to the general procedure for the cleavage of silyl ethers, compound **31** (0.10 g, 0.17 mmol) was treated with a solution of TBAF (0.19 mL, 1 M in THF, 0.19 mmol) to afford, after purification by column chromatography (C_{18} - SiO_2 , CH_3CN), 0.08 g (98%) of **32** as a yellow oil. **$^1\text{H-NMR}$** (400.13 MHz, CDCl_3): δ 7.65 (d, J = 16.1 Hz, 1H, H3), 7.62 (s, 1H, H3'), 7.43 (d, J = 7.6 Hz, 1H, H5' or H6'), 7.26 (s, 1H, H6' or H5'), 6.95 (s, 1H, H6''), 6.58 (s, 1H, H3''), 6.46 (d, J = 16.1 Hz, 1H, H2), 4.82 (br, 1H, OH), 4.28 (q, J = 7.2 Hz, 2H, $\text{COOCH}_2\text{CH}_3$), 2.11 (s, 6H, 3x AdCH₂), 2.07 (s, 3H, ArCH₃ or 3x AdCH), 2.05

(s, 3H, 3x AdCH or ArCH₃), 1.77 (br, 6H, 3x AdCH₂), 1.35 (t, $J = 7.2$ Hz, 3H, COOCH₂CH₃) ppm. **¹³C-NMR** (100.62 MHz, CDCl₃): δ 167.0 (s, CO₂Et), 154.5 (s), 143.1 (d), 142.9 (s), 134.6 (s), 134.4 (s), 133.7 (s), 132.2 (d), 130.6 (s), 128.7 (d), 128.2 (d), 126.0 (d), 119.1 (d), 118.1 (d), 60.8 (t, COOCH₂CH₃), 40.6 (t, 3x AdCH₂), 37.0 (t, 3x AdCH₂), 36.4 (s, AdC), 29.0 (d, 3x AdCH), 19.1 (q, ArCH₃), 14.3 (q, CO₂CH₂CH₃) ppm. **IR** (NaCl): ν 3400–2400 (br, O-H), 2853 (m, C-H), 1717 (s, C=O), 1639 (s), 1606 (m), 1483 (s), 1390 (s), 1259 (s), 1174 (s), 873 (s), 838 (s) cm⁻¹. **MS (EI⁺)**: m/z (%) 453 ([M+1]⁺ [³⁷Cl], 11), 452 (M⁺ [³⁷Cl], 40), 451 ([M+1]⁺ [³⁵Cl], 34), 450 (M⁺ [³⁵Cl], 100), 393 (18), 356 (11). **HRMS**: calcd for C₂₈H₃₁³⁵ClO₃, 450.1962 and C₂₈H₃₁³⁷ClO₃, 452.1932; found, 450.1944 and 452.1934.

(E)-Ethyl 3-[5'-(Adamant-1-yl)-2-chloro-4'-[(2-methoxyethoxy)methoxy]-2'-methylbiphenyl-4-yl]acrylate (33)—According to the general procedure for the protection of phenols with MEMCl, compound **32** (0.009 g, 0.02 mmol) was treated with NaH (0.001 g, 60% in mineral oil, 0.04 mmol) and MEMCl (0.01 mL, 0.02 mmol) to afford, after purification by column chromatography (C₁₈-SiO₂, CH₃CN), 0.01 g (97%) of **33** as a yellow oil. **¹H-NMR** (400.13 MHz, CDCl₃): δ 7.66 (d, $J = 16.0$ Hz, 1H, H₃), 7.61 (s, 1H, H_{3'}), 7.42 (d, $J = 8.0$ Hz, 1H, H_{5'} or H_{6'}), 7.25 (d, $J = 8.0$ Hz, 1H, H_{6'} or H_{5'}), 7.06 (s, 1H, H_{6''}), 6.96 (s, 1H, H_{3''}), 6.46 (d, $J = 16.0$ Hz, 1H, H₂), 5.38 (d, $J = 6.4$ Hz, 1H, OCH₂O), 5.34 (d, $J = 6.4$ Hz, 1H, OCH₂O), 4.28 (q, $J = 7.2$ Hz, 2H, COOCH₂CH₃), 3.90 (t, $J = 4.4$ Hz, 2H, O(CH₂)₂O), 3.63 (t, $J = 4.4$ Hz, 2H, O(CH₂)₂O), 3.42 (s, 3H, OCH₂O(CH₂)₂OCH₃), 2.09 (s, 9H, 3x AdCH₂ + ArCH₃ or 3x AdCH), 2.05 (s, 3H, 3x AdCH or ArCH₃), 1.76 (br, 6H, 3x AdCH₂), 1.35 (t, $J = 7.2$ Hz, 3H, COOCH₂CH₃) ppm. **¹³C-NMR** (100.62 MHz, CDCl₃): δ 166.7 (s, CO₂Et), 156.2 (s), 142.8 (d), 142.7 (s), 135.8 (s), 134.7 (s), 134.6 (s), 134.5 (s), 132.1 (d), 131.6 (s), 128.7 (d), 127.9 (d), 126.0 (d), 119.3 (d), 115.8 (d), 93.4 (t, OCH₂O), 71.6 (t, O(CH₂)₂O), 67.9 (t, O(CH₂)₂O), 60.6 (t, COOCH₂CH₃), 59.0 (q, OCH₂O(CH₂)₂OCH₃), 40.8 (t, 3x AdCH₂), 37.0 (t, 3x AdCH₂), 36.8 (s, AdC), 29.0 (d, 3x AdCH), 19.5 (q, ArCH₃ or COOCH₂CH₃), 14.3 (q, COOCH₂CH₃ or ArCH₃) ppm. **IR** (NaCl): ν 2902 (s, C-H), 2850 (s, C-H), 1712 (s, C=O), 1639 (s), 1483 (m), 1452 (m), 1252 (m), 1256 (s), 1172 (s), 1152 (s), 1017 (s), 977 (s), 861 (s), 834 (s), 755 (s) cm⁻¹. **MS (EI⁺)**: m/z (%) 541 ([M+1]⁺ [³⁷Cl], 3), 540 (M⁺ [³⁷Cl], 10), 539 ([M+1]⁺ [³⁵Cl], 30), 538 (M⁺ [³⁵Cl], 25), 464 (10), 462 (22), 89 ([C₄H₉O₂]⁺, 100). **HRMS**: calcd for C₃₂H₃₉³⁵ClO₅, 538.2486 and C₃₂H₃₉³⁷ClO₅, 540.2457; found, 538.2480 and 540.2458.

(E)-3-[5'-(Adamant-1-yl)-2-chloro-4'-[(2-methoxyethoxy)methoxy]-2'-methylbiphenyl-4-yl]acrylic Acid (34)—In accordance to the general procedure for hydrolysis of esters, compound **33** (0.025 g, 0.046 mmol) was treated with Na₂CO₃ (0.23 mL, 2 M in H₂O, 0.46 mmol) to provide, after purification by column chromatography (C₁₈-SiO₂, CH₃CN), 0.023 g (97%) of **34** as a yellow oil. **¹H-NMR** (400.13 MHz, CD₂Cl₂): δ 7.75 (d, $J = 16.0$ Hz, 1H, H₃), 7.67 (d, $J = 1.6$ Hz, 1H, H_{3'}), 7.50 (d, $J = 8.0$, 1.6 Hz, 1H, H_{5'}), 7.28 (d, $J = 8.0$ Hz, 1H, H_{6'}), 7.02 (s, 1H, H_{6''}), 6.96 (s, 1H, H_{3''}), 6.50 (d, $J = 16.3$ Hz, 1H, H₂), 5.30–5.33 (m, 2H, OCH₂O), 3.86 (t, $J = 4.7$ Hz, 2H, O(CH₂)₂O), 3.59 (t, $J = 4.7$ Hz, 2H, O(CH₂)₂O), 3.36 (s, 3H, OCH₂O(CH₂)₂OCH₃), 2.09 (s, 6H, 3x AdCH₂), 2.08 (s, 3H, ArCH₃ or 3x AdCH), 2.03 (s, 3H, 3x AdCH or ArCH₃), 1.76 (s, 6H, 3x AdCH₂) ppm. **¹³C-NMR** (100.62 MHz, CDCl₃): δ 170.7 (s, CO₂H), 156.6 (s), 145.4 (d), 143.6 (s), 136.3 (s), 135.0 (s), 134.9 (s), 134.8 (s), 132.7 (d), 131.9 (s), 129.3 (d), 128.2 (d), 126.8 (d), 118.5 (d), 116.2 (d), 93.8 (t, OCH₂O), 72.0 (t, O(CH₂)₂O), 68.5 (t, O(CH₂)₂O), 59.0 (q, OCH₂O(CH₂)₂OCH₃), 41.2 (t, 3x AdCH₂), 37.4 (t, 3x AdCH₂), 37.2 (s, AdC), 30.1 (t), 29.6 (d, 3x AdCH), 19.6 (q, ArCH₃) ppm. **IR** (NaCl): ν 3100–2500 (br, O-H), 2960 (m, C-H), 2904 (s, C-H), 1641 (d, C=O), 1564 (s, C=O), 1484 (m), 1456 (m), 1363 (s), 1100 (m), 1014 (s), 747 (s) cm⁻¹. **MS (EI⁺)**: m/z (%) 513 ([M+1]⁺ [³⁷Cl], 21), 512 (M⁺ [³⁷Cl], 21), 511 ([M+1]⁺ [³⁵Cl], 25), 510 (M⁺ [³⁵Cl], 40), 437 (16), 436 (18), 435 (38), 434 (20), 433 (21), 429 (16), 397 (11), 395 (12), 392 (13), 391 (40), 167 (22), 155 (38), 154 (100), 151 (22).

(E)-3-[5'-(Adamant-1-yl)-2-chloro-4'-hydroxy-2'-methylbiphenyl-4-yl]acrylic Acid (35)—According to the general procedure for hydrolysis of esters, treatment of compound **32** (0.006 g, 0.013 mmol) with Na₂CO₃ (0.07 mL, 2 M in H₂O, 0.13 mmol) for 3 h at 70 °C provided, after purification by column chromatography on silica gel (70:30 AcOEt/hexane), 0.006 g (99%) of **35** as a colourless oil. **¹H-NMR** (400.13 MHz, CDCl₃): δ 7.75 (d, *J* = 16.0 Hz, 1H, H3), 7.64 (s, 1H, H3), 7.45 (d, *J* = 8.0 Hz, 1H, H5 or H6), 7.27 (d, *J* = 8.0 Hz, 1H, H6 or H5), 6.94 (s, 1H, H6'), 6.58 (s, 1H, H3'), 2.11 (s, 6H, 3x AdCH₂), 2.04 (s, 6H, 3x AdCH + ArCH₃), 1.76 (br, 6H, 3x AdCH₂) ppm. **¹³C-NMR** (100.62 MHz, CDCl₃): δ 170.9 (s, CO₂H), 154.1 (s), 145.3 (d), 143.2 (s), 134.7 (s), 134.5 (s), 134.3 (s), 133.8 (s), 132.3 (d), 130.9 (s), 129.0 (d), 128.4 (d), 126.3 (d), 118.1 (d, 2x), 40.7 (t, 3x AdCH₂), 37.0 (t, 3x AdCH₂), 36.4 (s, AdC), 29.0 (d, 3x AdCH), 19.1 (q, ArCH₃) ppm. **IR** (NaCl): ν 3500–2400 (br, O-H), 2905 (s, C-H), 2850 (s, C-H), 1689 (s, C=O), 1631 (s), 1401 (s), 1263 (s), 1213 (s), 1144 (s) cm⁻¹. **MS (EI⁺)**: *m/z* (%) 425 ([M+1]⁺ [³⁷Cl], 10), 424 (M⁺ [³⁷Cl], 38), 423 ([M+1]⁺ [³⁵Cl], 30), 422 (M⁺ [³⁵Cl], 100), 367 (10), 365 (26), 328 (14). **HRMS**: calcd for C₂₆H₂₇³⁵ClO₃, 422.1649 and C₂₆H₂₇³⁷ClO₃, 424.1619; found, 422.1658 and 424.1638.

6.2. Biology

6.2.1. Cell Proliferation assays—All cancer cell lines were obtained from ATCC and grown following ATCC's recommendations. AdArs were prepared in DMSO as 4 mM stock solutions and diluted in basic DMEM as 20x dilutions.

Cell proliferation assays were performed in 96 well plates. PC-3, SkOV3, A549 cells (3,000 cells per well), MiaPaCa-2, BxPC-3 (4,000 cells per well), T-47D, and MDA-MB-468 (5,000 cells per well) were seeded in complete growing medium the day before treatment and allowed to attach. Medium was changed to 0.5% FBS containing medium just before AdAr exposure. Jurkat T cells (10,000 cells per well) were resuspended (10⁵ cells/mL) in RPMI supplemented with 0.5% FBS and seeded in 96 well plates immediately before AdAr treatment. Cells were treated with increasing concentrations of the AdArs and, when indicated, 10 µL of a 5mg/mL 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide (MTT) solution were added. After 4 h incubation at 37 °C, 100 µL 10% SDS in 10 mM HCl were added to solubilise the formazan crystals. The absorbance at 595 nm was measured in a Molecular Devices SpectraMax reader and the background obtained in the absence of cells was subtracted. The percentage of cell viability was calculated with respect to controls (100%), which were incubated with an equivalent amount of solvent DMSO (≤0.1% v/v). All experiments were performed at least twice with triplicate points.

6.2.2. DEVDase measurement—To measure caspase activity we adapted a fluorescence enzymatic assay [27] into a 96 well plate format. Jurkat T cells (40,000 cells per well; 10⁶ cells/mL) resuspended in RPMI containing 0.5% FBS were seeded and immediately treated with AdArs. After 4 h of treatment, cells were lysed by adding 10 µL 5x CE buffer (25 mM PIPES pH 7, 25 mM KCl, 5 mM EGTA, 1mM DTT, 10 µM cytochalasin B, 0.5% NP-40, and a mixture of protease inhibitors consisting of 1 mM PMSF, 1 µg/mL leupeptine, and 1 µg/mL aprotinin) followed by 30 min incubation at 4 °C. Cell extracts were then diluted with 50 µL 2x caspase buffer (50 mM HEPES pH 7.4, 100 mM NaCl, 1 mM EDTA, 5 mM DTT, 0.1% CHAPS and 10% sucrose) containing 100 µM of Ac-DEVD-AFC (Enzyme System Products). Reactions were incubated at 37 °C for 30 minutes, and the release of free AFC was measured every two minutes at 510 nm emission upon excitation at 390 nm, using a Victor2 microplate reader (Perkin Elmer).

6.2.3. RAR/RXR transactivation profiling—Gal4-LBD fusion proteins contain residues 1–147 encoding the DNA binding domain of Gal4 in pSG424 [87] fused to the LBDs of hRARα (residues 156–462), hRARβ (residues 169–448), hRARγ (residues 178–454), or

mRXR α (residues 218–467). CV-1 cells (20,000 cells per well) were transfected in 96 well plates with 10 ng of each of the Gal4-LBD expression vectors together with 100 ng UAS-luciferase reporter and 25 ng β -galactosidase expression vector (pCH110) using Superfect transfection reagent. 16 h after transfection, the medium was removed and fresh medium containing 5% charcoal-treated FBS was added, followed by AdAr stimulation for 6 h (RAR α , RAR β , RXR α) or 20 h (RAR γ). Cells were washed once with PBS, lysed and assayed for luciferase and β -galactosidase activities using a Dual-Light chemiluminescent assay (Tropix).

6.2.4. Molecular Docking—The genetic algorithm [88] implemented in AutoDock [89] and the human RXR α (PDB code 1k74) [62] upon removal of the 9-*cis*-retinoic acid ligand as the target protein were used to generate different RXR α -bound conformers of **35** by randomly changing torsion angles and the overall orientation of the molecule. A volume for exploration was defined in the shape of a three-dimensional cubic grid (80 x 80 x 80 Å³) [90] with a spacing of 0.3 Å that enclosed the residues that are known to make up the agonist binding pocket. At each grid point, the receptor's atomic affinity potentials for carbon, oxygen, and hydrogen atoms present in the studied ligands were pre-calculated for rapid intra- and intermolecular energy evaluation of each docked conformation.

Acknowledgements

This work was supported by funds from the Spanish MEC (SAF04-07131, SAF2007-63880-FEDER to A. R. de L.; Juan de la Cierva Contract to F. R.-B.), Xunta de Galicia (PGIDIT05PXIC31403PN, 08CSA052383PR from DXI+D +I, Consolidación 2006/15 from DXPCTSUG to A. R. de L.), and NIH grant (CA55681 to F.J.P.). We thank Dr. Efrén Pérez and Dr. Susana Alvarez for the UVI2024 and UVI3003 ligands, M. Ptashne for the pSG424 expression vector, and Ming Zhao for excellent technical assistance.

Abbreviations

9cRA	9- <i>cis</i> -retinoic acid
AdAr	adamantyl arotinoid
atRA	all- <i>trans</i> -retinoic acid
IKK	I κ B kinase
JNK	cJun N-terminal kinase
LBD	ligand binding domain
MAPK	mitogen activated protein kinase
NFκB	nuclear factor- κ B
RAR	retinoic acid receptor
RRM	

retinoid-related molecule

RXR

retinoid X receptor

SHP

short heterodimer partner

Reference List

- Altucci L, Gronemeyer H. *Nat Rev Cancer* 2001;1:181–193. [PubMed: 11902573]
- Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, de Lera AR, Lotan R, Mangelsdorf DJ, Gronemeyer H. *Pharmacol Rev* 2006;58:712–725. [PubMed: 17132850]
- Germain P, Chambon P, Eichele G, Evans RM, Lazar MA, Leid M, de Lera AR, Lotan R, Mangelsdorf DJ, Gronemeyer H. *Pharmacol Rev* 2006;58:760–772. [PubMed: 17132853]
- Laudet, V.; Gronemeyer, H. *The Nuclear Receptor Facts Book*. Academic Press; San Diego: 2002.
- Glass CK, Rosenfeld MG. *Genes Dev* 2000;14:121–141. [PubMed: 10652267]
- Germain P, Altucci L, Bourguet W, Rochette-Egly C, Gronemeyer H. *Pure Appl Chem* 2003;75:1619–1664.
- Ortiz MA, Bayon Y, Lopez-Hernandez FJ, Piedrafita FJ. *Drug Resist Updat* 2002;5:162–175. [PubMed: 12237083]
- Castaigne S, Chomienne C, Daniel MT, Ballerini P, Berger R, Fenaux P, Degos L. *Blood* 1990;76:1704–1709. [PubMed: 2224119]
- Henney JE. *JAMA* 2000;283:1131. [PubMed: 10703765]
- Farol LT, Hymes KB. *Expert Rev Anticancer Ther* 2004;4:180–188. [PubMed: 15056048]
- Bernard A, Bernardon JM, Delescluse C, Martin B, Lenoir MC, Maignan J, Charpentier B, Pilgrim WR, Reichert U, Shroot B. *Biochem Biophys Res Commun* 1992;186:977–983. [PubMed: 1323296]
- Buck J, Grun F, Derguini F, Chen Y, Kimura S, Noy N, Hammerling U. *J Exp Med* 1993;178:675–680. [PubMed: 8340762]
- Korichneva I, Hämmerling U. *J Cell Sci* 1999;112:2521–2528. [PubMed: 10393808]
- Delia D, Aiello A, Lombardi L, Pellici PG, Grignani F, Formelli F, Menard S, Costa A, Veronesi U, Pierotti MA. *Cancer Res* 1993;53:6036–6041. [PubMed: 8261419]
- Chun KH, Benbrook DM, Berlin KD, Hong WK, Lotan R. *Cancer Res* 2003;63:3826–3832. [PubMed: 12839980]
- Piedrafita FJ, Ortiz MA. *Current Cancer Therapy Reviews* 2006;2:185–198.
- Shao ZM, Dawson MI, Li XS, Rishi AK, Sheikh MS, Han QX, Ordóñez V, Shroot B, Fontana JA. *Oncogene* 1995;11:493–504. [PubMed: 7630633]
- Hsu CA, Rishi AK, Su-Li X, Gerald TM, Dawson MI, Schiffer C, Reichert U, Shroot B, Poirer GC, Fontana JA. *Blood* 1997;89:4470–4479. [PubMed: 9192771]
- Sun SY, Yue P, Chandraratna RA, Tesfagzi Y, Hong WK, Lotan R. *Mol Pharmacol* 2000;58:508–514. [PubMed: 10953043]
- Bayon Y, Ortiz MA, Lopez-Hernandez FJ, Gao F, Karin M, Pfahl M, Piedrafita FJ. *Mol Cell Biol* 2003;23:1061–1074. [PubMed: 12529410]
- Piedrafita FJ, Pfahl M. *Mol Cell Biol* 1997;17:6348–6358. [PubMed: 9343396]
- Marchetti P, Zamzami N, Joseph B, Schraen-Maschke S, Mereau-Richard C, Costantini P, Metivier D, Susin SA, Kroemer G, Formstecher P. *Cancer Res* 1999;59:6257–6266. [PubMed: 10626821]
- Li Y, Lin B, Agadir A, Liu R, Dawson MI, Reed JC, Fontana JA, Bost F, Hobbs PD, Zheng Y, Chen GQ, Shroot B, Mercola D, Zhang X. *Moll Cell Biol* 1998;18:4719–4731.
- Sun SY, Yue P, Wu GS, El Deiry WS, Shroot B, Hong WK, Lotan R. *Cancer Res* 1999;59:2829–2833. [PubMed: 10383141]
- Belzacq AS, El Hamel C, Vieira HL, Cohen I, Haouzi D, Metivier D, Marchetti P, Brenner C, Kroemer G. *Oncogene* 2001;20:7579–7587.

26. Lopez-Hernandez FJ, Ortiz MA, Bayon Y, Piedrafita FJ. *Mol Cancer Ther* 2003;2:255–263. [PubMed: 12657720]
27. Lopez-Hernandez FJ, Ortiz MA, Bayon Y, Piedrafita FJ. *Cell Death Differ* 2004;11:154–164. [PubMed: 14576769]
28. Sun SY, Yue P, Hong WK, Lotan R. *Cancer Res* 2000;60:7149–7155. [PubMed: 11156424]
29. Sun SY, Yue P, Hong WK, Lotan R. *Cancer Res* 2000;60:6537–6543. [PubMed: 11103825]
30. Chun KH, Pfahl M, Lotan R. *Oncogene* 2005;24:3669–3677. [PubMed: 15782141]
31. Ortiz MA, Lopez-Hernandez FJ, Bayon Y, Pfahl M, Piedrafita FJ. *Cancer Res* 2001;61:8504–8512. [PubMed: 11731435]
32. Zhang J, Reedy MC, Hannun YA, Obeid LM. *J Cell Biol* 1999;145:99–108. [PubMed: 10189371]
33. Ponzanelli I, Gianni M, Giavazzi R, Garofalo A, Nicoletti I, Reichert U, Erba E, Rambaldi A, Terao M, Garattini E. *Blood* 2000;95:2672–2682. [PubMed: 10753850]
34. Sakaue M, Adachi H, Dawson M, Jetten AM. *Cell Death Differ* 2001;8:411–424. [PubMed: 11550093]
35. Holmes WF, Soprano DR, Soprano KJ. *J Biol Chem* 2002;277:45408–45419. [PubMed: 12237293]
36. Garattini E, Parrella E, Diomede L, Gianni' M, Kalac Y, Merlini L, Simoni D, Zanier R, Ferrara FF, Chiarucci I, Carminati P, Terao M, Pisano C. *Blood* 2004;103:194–207. [PubMed: 12958071]
37. Karin M, Cao Y, Greten FR, Li ZW. *Nature Rev Cancer* 2002;2:301–310. [PubMed: 12001991]
38. Lorenzo P, Alvarez R, Ortiz MA, Alvarez S, Piedrafita FJ, de Lera AR. *J Med Chem* 2008;51:5431–5440. [PubMed: 18702457]
39. Farhana L, Dawson MI, Fontana JA. *Cancer Res* 2005;65:4909–4917. [PubMed: 15930313]
40. Jin F, Liu X, Zhou Z, Yue P, Lotan R, Khuri FR, Chung LW, Sun SY. *Cancer Res* 2005;65:6354–6363. [PubMed: 16024638]
41. Dawson MI, Hobbs PD, Peterson VJ, Leid M, Lange CW, Feng KC, Chen G, Gu J, Li H, Kolluri SK, Zhang X, Zhang Y, Fontana JA. *Cancer Res* 2001;61:4723–4730. [PubMed: 11406543]
42. Keedwell RG, Zhao Y, Hammond LA, Qin S, Tsang KY, Reitmair A, Molina Y, Okawa Y, Atangan LI, Shurland DL, Wen K, Wallace DM, Bird R, Chandraratna RA, Brown G. *Cancer Res* 2004;64:3302–3312. [PubMed: 15126374]
43. Zhang Y, Dawson MI, Mohammad R, Rishi AK, Farhana L, Feng KC, Leid M, Peterson V, Zhang XK, Edelstein M, Eilander D, Biggar S, Wall N, Reichert U, Fontana JA. *Blood* 2002;100:2917–2925. [PubMed: 12351403]
44. Cincinelli R, Dallavalle S, Merlini L, Penco S, Pisano C, Carminati P, Giannini G, Vesci L, Gaetano C, Illy B, Zuco V, Supino R, Zunino F. *J Med Chem* 2003;46:909–912. [PubMed: 12620066]
45. Cincinelli R, Dallavalle S, Nannei R, Carella S, De Zani D, Merlini L, Penco S, Garattini E, Giannini G, Pisano C, Vesci L, Carminati P, Zuco V, Zanchi C, Zunino F. *J Med Chem* 2005;48:4931–4946. [PubMed: 16033272]
46. Zhang Y, Dawson MI, Ning Y, Polin L, Parchment RE, Corbett T, Mohammad AN, Feng KC, Farhana L, Rishi AK, Hogge D, Leid M, Peterson VJ, Zhang XK, Mohammad R, Lu JS, Willman C, VanBuren E, Biggar S, Edelstein M, Eilender D, Fontana JA. *Blood* 2003;102:3743–3752. [PubMed: 12893763]
47. Dawson MI, Harris DL, Liu G, Hobbs PD, Lange CW, Jong L, Bruey-Sedano N, James SY, Zhang XK, Peterson VJ, Leid M, Farhana L, Rishi AK, Fontana JA. *J Med Chem* 2004;47:3518–3536. [PubMed: 15214780]
48. Farhana L, Dawson MI, Leid M, Wang L, Moore DD, Liu G, Xia Z, Fontana JA. *Cancer Res* 2007;67:318–325. [PubMed: 17210713]
49. Charpentier B, Bernardon JM, Eustache J, Millois C, Martin B, Michel S, Shroot B. *J Med Chem* 1995;38:4993–5006. [PubMed: 8544175]
50. Dawson MI, Xia Z, Liu G, Fontana JA, Farhana L, Patel BB, Arumugarajah S, Bhuiyan M, Zhang XK, Han YH, Stallcup WB, Fukushi J, Mustelin T, Tautz L, Su Y, Harris DL, Waleh N, Hobbs PD, Jong L, Chao WR, Schiff LJ, Sani BP. *J Med Chem* 2007;50:2622–2639. [PubMed: 17489579]
51. Gronemeyer H, Gustafsson JA, Laudet V. *Nat Rev Drug Discov* 2004;3:950–964. [PubMed: 15520817]
52. de Lera AR, Bourguet W, Altucci L, Gronemeyer H. *Nat Rev Drug Discov* 2007;6:811–820. [PubMed: 17906643]

53. Kotha S, Lahiri K, Kashinath D. *Tetrahedron* 2002;58:9633–9695.
54. Chaumeil H, Signorella S, Le Drian C. *Tetrahedron* 2000;56:9655–9662.
55. Chittiboyina AG, Venkatraman MS, Mizuno CS, Desai PV, Patny A, Benson SC, Ho CI, Kurtz TW, Pershadsingh HA, Avery MA. *J Med Chem* 2006;49:4072–4084. [PubMed: 16821769]
56. Bates RW, Rama-Devi T. *Synlett* 1995:1151–1152.
57. Cockerill SG, Easterfield HJ, Percy JM, Pintat S. *J Chem Soc Perkin Trans* 2000;1:2591–2599.
58. Solodenko W, Schoen U, Messinger J, Glinschert A, Kirschning A. *Synlett* 2004:1699–1702.
59. Boatright KM, Salvesen GS. *Biochem Soc Symp* 2003:233–242. [PubMed: 14587296]
60. Benoit G, Altucci L, Flexor M, Ruchaud S, Lillehaug J, Raffelsberger W, Gronemeyer H, Lanotte M. *EMBO J* 1999;18:7011–7018. [PubMed: 10601023]
61. Nahoum V, Perez E, Germain P, Rodriguez-Barrios F, Manzo F, Kammerer S, Lemaire G, Hirsch O, Royer CA, Gronemeyer H, de Lera AR, Bourguet W. *Proc Natl Acad Sci U S A* 2007;104:17323–17328. [PubMed: 17947383]
62. Xu HE, Lambert MH, Montana VG, Plunket KD, Moore LB, Collins JL, Oplinger JA, Kliewer SA, Gampe J, McKee DD, Moore JT, M WT. *Proc Natl Acad Sci U S A* 2001;98:13919–13924. [PubMed: 11698662]
63. Dawson, MI.; Okamura, WH. *Chemistry and biology of synthetic retinoids*. CRC Press; Boca Raton: 1990.
64. Sporn, MB.; Roberts, AB.; Goodman, DSe. *The retinoids: Biology, Chemistry, and Medicine*. Raven Press, Ltd.; New York, NY: 1994.
65. Loeliger P, Bollag W, Mayer H. *Eur J Med Chem* 1980;15:9–15.
66. Fontana JA, Rishi AK. *Leukemia* 2002;16:463–472. [PubMed: 11960323]
67. Pfahl M, Piedrafita FJ. *Oncogene* 2003;22:9058–9062. [PubMed: 14663484]
68. Guo YL, Baysal K, Kang B, Yang LJ, Williamson JR. *J Biol Chem* 1998;273:4027–4034. [PubMed: 9461593]
69. Hu YL, Li S, Shyy JY, Chien S. *Am J Physiol* 1999;277:H1593–H1599. [PubMed: 10516199]
70. Wang WH, Gregori G, Hullinger RL, Andrisani OM. *Mol Cell Biol* 2004;24:10352–10365. [PubMed: 15542843]
71. Venugopal SK, Chen J, Zhang Y, Clemens D, Follenzi A, Zern MA. *J Biol Chem* 2007;282:31900–31908. [PubMed: 17848570]
72. Bourguet W, Vivat V, Wurtz JM, Chambon P, Gronemeyer H, Moras D. *Mol Cell* 2000;5:289–298. [PubMed: 10882070]
73. Takamatsu K, Takano A, Yakushiji N, Morishita K, Matsuura N, Makishima M, Ali HI, Akaho E, Tai A, Sasaki K, Kakuta H. *ChemMedChem* 2008;3:454–460. [PubMed: 18157857]
74. Takamatsu K, Takano A, Yakushiji N, Morohashi K, Morishita K, Matsuura N, Makishima M, Tai A, Sasaki K, Kakuta H. *ChemMedChem* 2008;3:780–787. [PubMed: 18297677]
75. Liby KT, Yore MM, Sporn MB. *Nat Rev Cancer* 2007;7:357–369. [PubMed: 17446857]
76. Boehm MF, Zhang L, Zhi L, McClurg MR, Berger E, Wagoner M, Mais DE, Suto CM, Davies JA, Heyman RA. *J Med Chem* 1995;38:3146–3155. [PubMed: 7636877]
77. Vuligonda V, Thacher SM, Chandraratna RA. *J Med Chem* 2001;44:2298–2303. [PubMed: 11428923]
78. Balasubramanian S, Chandraratna RA, Eckert RL. *Carcinogenesis* 2004;25:1377–1385. [PubMed: 14976133]
79. Crowe DL, Chandraratna RA. *Breast Cancer Res* 2004;6:R546–R555. [PubMed: 15318936]
80. Rendi MH, Suh N, Lamph WW, Krajewski S, Reed JC, Heyman RA, Berchuck A, Liby K, Risingsong R, Royce DB, Williams CR, Sporn MB. *Cancer Res* 2004;64:3566–3571. [PubMed: 15150113]
81. Wu K, DuPre E, Kim H, Tin U, Bissonnette RP, Lamph WW, Brown PH. *Breast Cancer Res Treat* 2006;96:147–157. [PubMed: 16273314]
82. Benoit GR, Flexor M, Besancon F, Altucci L, Rossin A, Hillion J, Balajthy Z, Legres L, Segal-Bendirdjian E, Gronemeyer H, Lanotte M. *Mol Endocrinol* 2001;15:1154–1169. [PubMed: 11435615]

83. Altucci L, Rossin A, Hirsch O, Nebbioso A, Vitoux D, Wilhelm E, Guidez F, De Simone M, Schiavone EM, Grimwade D, Zelent A, de The H, Gronemeyer H. *Cancer Res* 2005;65:8754–8765. [PubMed: 16204045]
84. Agarwal VR, Bischoff ED, Hermann T, Lamph WW. *Cancer Res* 2000;60:6033–6038. [PubMed: 11085524]
85. Kim HT, Kong G, DeNardo D, Li Y, Uray I, Pal S, Mohsin S, Hilsenbeck SG, Bissonnette R, Lamph WW, Johnson K, Brown PH. *Cancer Res* 2006;66:12009–12018. [PubMed: 17178900]
86. Eppe R, Russo R, Azimioara M, Cow C, Xie Y, Wang X, Wityak J, Karanewsky D, Gerken A, Iskandar M, Saez E, M SH, Tian SS. *Bioorg Med Chem Lett* 2006;4376–4380. [PubMed: 16750626]
87. Sadowski I, Ma J, Triezenberg S, Ptashne M. *Nature (London)* 1988;335:563–564. [PubMed: 3047590]
88. Morris GM, Goodsell DS, Halliday RS, Huey R, Hart WE, Belew RK, Olson AJ. *J Comp Chem* 1998;19:1639–1662.
89. Morris, GM.; Goodsell, DS.; Huey, R.; Hart, WE.; Halliday, S.; Belew, R.; Olson, AJ. La Jolla, CA. 1999. p. 92037-1000.
90. Goodford PJ. *J Med Chem* 1985;28:849–857. [PubMed: 3892003]

Figure 1.
Representative adamantyl arotinoids (AdArs).

Figure 2.

Antiproliferative activity of AdArs against Jurkat T leukemia cells. Jurkat cells were incubated with increasing concentrations (between 62.5 nM and 2 μM) of phenols (A) or MEM-derivatives (B) for two days, when cell proliferation was measured by MTT. The results of a typical experiment performed in triplicate are shown.

Figure 3. Induction of apoptosis by AdArs. Jurkat cells were incubated with 1 (grey) or 4 (black) μM of the indicated compounds for 4 h, when cells were lysed and assayed for DEVDase activity. Control cells (no) were incubated with 0.1% (v/v) DMSO. The experiment was performed three times in duplicate and shown here are the results of one typical experiment. ND: not determined.

Figure 4.

Effect of AdArs on RAR α transactivation activity. (A) CV-1 cells were transfected with Gal4-RAR α and stimulated with 1 μ M atRA or 2 μ M of the indicated analogs. Luciferase activity was determined after 6 h of stimulation following standard procedures and normalized by β -galactosidase. (B) RAR antagonist activity of AdArs. Transfected CV-1 cells were co-stimulated with 20 nM of atRA together with increasing concentrations of the indicated analogs. Phenols and MEM derivatives are represented by closed and open symbols, respectively. For comparison, the antagonist activity of UVI2024 and MX781 **9** were also evaluated. The percentage of the maximum activity measured with respect to cells stimulated with 20 nM of atRA alone is represented. Data are the average $\pm$ standard deviation of two independent experiments performed with triplicate points.

Figure 5.

Activation of RXR α by AdArs. (A) Gal4-RXR α -transfected CV-1 cells were stimulated with 1 μ M 9cRA **36** or 2 μ M of the indicated analogs for 6 h, when luciferase activity was measured. (B) CV-1 cells were stimulated with 1 μ M 9cRA **36** or 5 μ M of the indicated AdArs in the absence (black columns) or in the presence of 1 μ M UVI3003 **38** (grey columns) for 6 h, when luciferase and β -galactosidase activities were determined. RXR activating compounds were further titrated to estimate their EC₅₀ values (C). Luciferase activity in A and C represents the percentage of the maximum activity obtained in the presence of 1 μ M 9cRA **36**.

Figure 6.
RAR and RXR (ant)agonists used as control in transactivation studies.

Figure 7. Docking of adamantyl arotinoid **35** (in yellow) into the RXR α -binding pocket and close-up view highlighting the main interactions with the protein residues. For comparison, the structure of 9cRA (in grey) is superimposed.

Scheme 1.

Reagents and reaction conditions: (a) adamant-1-ol, H_2SO_4 , 25 °C, 2 h, 98%. (b) Et_3N , DMAP, TBDMSCl, 25 °C, 1.5 h, 88%. (c) *i. n*-BuLi, THF, -78 °C, 1 h; *ii.* $\text{B}(\text{O}^i\text{Pr})_3$, -78 to 25 °C, 18 h; *iii.* HCl, 25 °C, 1 h, 65%. (d) MeOH, TMSCHN_2 , 25 °C, 1.5 h, 98%. (e) $(\text{F}_3\text{CSO}_2)_2\text{O}$, pyridine, 0 °C, 1.5 h, 82%. (f) NaH, $(\text{EtO})_2\text{POCH}_2\text{CO}_2\text{Et}$, 0 °C, 4 h, 51%. (g), (h), (i) Suzuki coupling (see text). (j) TBAF, THF, 0 °C. (k) MEMCl, NaH, DMF, 25 °C. (l) Na_2CO_3 , MeOH, 70 °C.

Table 1
Inhibition of cancer cell proliferation by the novel AdArs.^a

	PC-3	SkOV3	A549	MiaPaCa-2	BxPC-3	T-47D	MB468
2	92.3 ± 1.4	67.0 ± 1.8	79.0 ± 4.0	76.1 ± 6.0	95.7 ± 0.2	62.7 ± 3.0	76.7 ± 1.3
25	66.7 ± 6.9	30.3 ± 1.6	15.9 ± 5.1	26.8 ± 5.5	49.2 ± 4.7	29.1 ± 4.2	11.1 ± 7.7
30	97.7 ± 0.8	87.0 ± 0.9	88.1 ± 2.1	91.5 ± 4.5	94.7 ± 0.5	55.8 ± 0.6	59.2 ± 2.2
35	68.7 ± 1.5	65.1 ± 0.8	23.7 ± 4.5	26.3 ± 4.1	36.0 ± 3.0	24.2 ± 4.8	24.9 ± 5.9
9	92.1 ± 2.3	61.5 ± 7.1	42.1 ± 5.6	74.9 ± 2.8	96.6 ± 0.4	50.6 ± 2.3	72.4 ± 1.3
24	52.2 ± 3.5	19.1 ± 4.1	7.9 ± 7.1	6.3 ± 3.4	14.0 ± 3.6	27.6 ± 3.9	25.3 ± 5.6
29	97.6 ± 1.1	71.2 ± 1.5	88.1 ± 3.7	63.7 ± 2.8	70.2 ± 4.7	46.1 ± 1.3	49.9 ± 2.2
34	72.0 ± 6.6	80.1 ± 0.6	51.1 ± 0.7	63.3 ± 4.5	45.8 ± 1.8	29.1 ± 3.3	42.0 ± 3.6

^aThe effect of AdArs on cancer cell proliferation was evaluated by MTT assay. Prostate (PC-3), ovarian (SKOV3), breast (T-47D, MDA-MB468), and pancreas (MiaPaCa-2, BxPC3) cancer cells were treated with 4 μM AdArs for 48 h. NSCLC cells (A549) were treated for 72 h before measuring cell viability. All experiments were performed one to three times with triplicate points and the average ± S.D. is shown.